

FILE 'HOME' ENTERED AT 11:59:19 ON 13 SEP 2000

=> file uspatfull

=> s mch or melanocyte concentrating hormone

571 MCH  
752 MELANOCYTE  
31634 CONCENTRATING  
19149 HORMONE  
1 MELANOCYTE CONCENTRATING HORMONE  
(MELANOCYTE(W)CONCENTRATING(W)HORMONE)  
L1 571 MCH OR MELANOCYTE CONCENTRATING HORMONE

=> s l1 and antagoni?

26360 ANTAGONI?  
L2 45 L1 AND ANTAGONI?

=> s l2 and weight

859860 WEIGHT  
L3 44 L2 AND WEIGHT

=> s l3 and eat? or appetite

18954 EAT?  
3116 APPETITE  
L4 3120 L3 AND EAT? OR APPETITE

=> s l3 and (eat? or appetite)

18954 EAT?  
3116 APPETITE  
L5 7 L3 AND (EAT? OR APPETITE)

=> d l-7

L5 ANSWER 1 OF 7 USPATFULL  
AN 2000:57883 USPATFULL  
TI Agouti-related proteins  
IN Stark, Kevin Lee, Newbury Park, CA, United States  
Luethy, Roland, Newbury Park, CA, United States  
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)  
PI US 6060589 20000509  
AI US 1998-33275 19980302 (9)  
RLI Division of Ser. No. US 1996-757541, filed on 27 Nov 1996, now patented,  
Pat. No. US 5766877  
PRAI US 1996-17505 19960510 (60)  
DT Utility  
LN.CNT 1734  
INCL INCLM: 530/350.000  
INCLS: 530/300.000; 435/069.100  
NCL NCLM: 530/350.000  
NCLS: 435/069.100; 530/300.000  
IC [7]  
ICM: C07K014-435  
EXF 530/350; 530/300; 435/69.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 7 USPATFULL  
AN 2000:17822 USPATFULL  
TI Treatment methods using homeopathic preparations of growth factors  
IN Brewitt, Barbara A., 5557 36.sup.th Ave. NE, Seattle, WA, United States  
98105  
PI US 6024734 20000215  
AI US 1997-855096 19970513 (8)  
RLI Continuation-in-part of Ser. No. US 1996-710040, filed on 10 Sep 1996,

now patented, Pat. No. US 5629286, issued on 13 May 1997 which is a continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, now abandoned

DT Utility  
LN.CNT 2005  
INCL INCLM: 604/500.000  
INCLS: 604/890.100; 514/002.000; 514/009.000; 514/019.000;  
530/351.000;  
530/303.000  
NCL NCLM: 604/500.000  
NCLS: 514/002.000; 514/009.000; 514/019.000; 530/303.000;  
530/351.000;  
604/890.100  
IC [7]  
ICM: A61M031-00  
EXF 604/500; 604/890.1; 604/501; 604/502; 604/503; 604/504; 604/505;  
604/514; 604/530

L5 ANSWER 3 OF 7 USPATFULL  
AN 1999:170609 USPATFULL  
TI Inhibitors of interleukin-1. $\beta$  converting enzyme  
IN Batchelor, Mark James, Cumnor Hill, United Kingdom  
Bebbington, David, Pewsey, United Kingdom  
Bemis, Guy W., Arlington, MA, United States  
Fridman, Wolf Herman, Paris, France  
Gillespie, Roger John, Nr. Malmesbury, United Kingdom  
Golec, Julian M. C., Swindon, United Kingdom  
Lauffer, David J., Stow, MA, United States  
Livingston, David J., Newtonville, MA, United States  
Matharu, Saroop Singh, Cricklade, United Kingdom  
Mullican, Michael D., Needham, MA, United States  
Murcko, Mark A., Holliston, MA, United States  
Murdoch, Robert, Highworth, United Kingdom  
Zelle, Robert E., Stow, MA, United States  
PA Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States  
(U.S.  
corporation)  
PI US 6008217 19991228  
AI US 1995-575641 19951220 (8)  
DT Utility  
LN.CNT 5446  
INCL INCLM: 514/221.000  
INCLS: 540/500.000  
NCL NCLM: 514/221.000  
NCLS: 540/500.000  
IC [6]  
ICM: C07D217-22  
ICS: C07D217-16; A61K031-47  
EXF 514/221; 540/500  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 7 USPATFULL  
AN 1999:128543 USPATFULL  
TI Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes  
IN Karanewsky, Donald S., Escondido, CA, United States  
Linton, Steven D., San Diego, CA, United States  
PA Idun Pharmaceuticals, Inc., La Jolla, CA, United States (U.S.  
corporation)  
PI US 5968927 19991019  
AI US 1997-928990 19970912 (8)  
RLI Continuation-in-part of Ser. No. US 1996-710621, filed on 20 Sep 1996,  
now abandoned  
DT Utility  
LN.CNT 2053  
INCL INCLM: 514/214.000  
INCLS: 540/520.000  
NCL NCLM: 514/079.000  
NCLS: 514/212.050; 540/520.000  
IC [6]

ICM: C07D487-06  
ICS: A61K031-55  
EXF 540/520; 514/214  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 7 USPATFULL  
AN 1999:63303 USPATFULL  
TI Combination therapy for the treatment of diabetes and obesity  
IN Smith, Roy G., Westfield, NJ, United States  
Cascieri, Margaret A., East Windsor, NJ, United States  
MacIntyre, Euan, Scotch Plains, NJ, United States  
MacNeil, Douglas J., Westfield, NJ, United States  
Menke, John G., Morganville, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5908830 19990601  
AI US 1997-961749 19971030 (8)  
PRAI US 1996-29233 19961031 (60)  
DT Utility  
LN.CNT 1080  
INCL INCLM: 514/012.000  
INCLS: 530/324.000; 530/350.000; 514/312.000; 424/309.000  
NCL NCLM: 514/012.000  
NCLS: 514/312.000; 530/324.000; 530/350.000  
IC [6]  
ICM: A61K038-00  
ICS: A61K031-24; C07K005-00; C07K016-00  
EXF 530/350; 530/324; 514/12  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 7 USPATFULL  
AN 1998:157312 USPATFULL  
TI Promotion of \*\*\*eating\*\*\* behavior  
IN Maratos-Flier, Eleftheria, Newton, MA, United States  
PA Joslin Diabetes Center, Inc., Boston, MA, United States (U.S. corporation)  
PI US 5849708 19981215  
AI US 1995-473022 19950606 (8)  
DT Utility  
LN.CNT 2285  
INCL INCLM: 514/013.000  
INCLS: 530/300.000; 530/317.000  
NCL NCLM: 514/013.000  
NCLS: 530/300.000; 530/317.000  
IC [6]  
ICM: A61K038-00  
EXF 530/300; 530/350; 530/317; 514/12; 514/14; 514/13  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 7 USPATFULL  
AN 1998:68802 USPATFULL  
TI Genes encoding art, an agouti-related transcript  
IN Stark, Kevin Lee, Newbury Park, CA, United States  
Luethy, Roland, Newbury Park, CA, United States  
PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)  
PI US 5766877 19980616  
AI US 1996-757541 19961127 (8)  
PRAI US 1996-17505 19960510 (60)  
DT Utility  
LN.CNT 1681  
INCL INCLM: 435/069.100  
INCLS: 536/023.500; 435/252.300; 435/254.110; 435/320.100; 435/325.000  
NCL NCLM: 435/069.100  
NCLS: 435/252.300; 435/254.110; 435/320.100; 435/325.000; 536/023.500  
IC [6]  
ICM: C12N015-12  
EXF 435/69.1; 435/325; 435/320.1; 435/252.3; 435/254.11; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 5 kwic

##### L5 ANSWER 5 OF 7 USPATFULL

AB . . . a metabolic rate modifying agent (e.g., a .beta..sub.3 adrenergic receptor agonist) and a feeding behavior modifying agent (e.g., a NPY5 \*\*\*antagonist\*\*\* ) is useful in the treatment of obesity and diabetes, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients. Methods of . . .  
SUMM Obesity, which can be defined as a body \*\*\*weight\*\*\* more than 20% above the ideal body \*\*\*weight\*\*\* , is a major health concern in Western societies, since it is accompanied by numerous complications such as hypertension, non-insulin dependent. . . as a consequence of increased ratio of caloric intake to energy expenditure. The molecular factors regulating food intake and body \*\*\*weight\*\*\* balance are incompletely understood. [B. Staels et al., J. Biol. Chem. 270(27), 15958 (1995); F. Lonnquist et al., Nature Medicine. . .  
SUMM . . . Chinese hamster ovary cells. See Emorine et al, Science, 1989, 245:1118-1121; and Liggett, Mol. Pharmacol., 1992, 42:634-637. The agonist and \*\*\*antagonist\*\*\* effects of the various compounds on the cultivated cells provide an indication of the antiobesity and antidiabetic effects of the. . .  
SUMM . . . protein (also known as leptin), a 167 amino acid polypeptide, has been shown to result in a dose- and time-dependent \*\*\*weight\*\*\* loss when administered to mice via intraperitoneal (IP) injection. [M. A. Pelleymounter et al., Science 269, 540 (1995)]. This \*\*\*weight\*\*\* loss effect is attributable to both a reduction in food intake and an increase in energy expenditure. Moreover, since both . . .  
SUMM . . . system, is another agent which has been identified as being connected with feeding behavior. Neuropeptide Y is involved in regulating \*\*\*eating\*\*\* behavior and is an extremely potent orixigenic agent [See e.g., Stanley, B. G., et al., Peptides 13: 581-587 (1992); Sahu, . . . In Endocrinology And Metabolism 4(7): 217-224 (1993)]. When administered intracerebroventricularly or injected into the hypothalamic paraventricular nucleus (PVN) it elicits \*\*\*eating\*\*\* in sated rats [Clark, J. T., et al., Endocrinology 115(1): 427-429 (1984); Stanley, B. G. and S. F. Leibowitz, Proc. . . Stanley, B. G. and S. F. Leibowitz, Life Sci. 35(26): 2635-42 (1984)] and intraventricular injection of antisera to NPY decreases \*\*\*eating\*\*\* [Stanley, B. G., et al., Peptides, supra; Sahu, A. and S. P. Kalra, supra]. It has been shown to stimulate \*\*\*appetite\*\*\* in a variety of species and at different stages of development [Stanley, B. G., Neuropeptide Y in multiple hypothalamic sites controls \*\*\*eating\*\*\* behavior, endocrine, and autonomic systems for body energy balance, in Neuropeptide Y, W. F. Colmers and C. Wahlestedt, Editor. 1993, . . .  
SUMM . . . Jun. 6, 1996], it has now been found that the other subtypes (e.g., NPY1, NPY4) may also be involved in \*\*\*weight\*\*\* control, for example by effects on metabolic rate.  
SUMM The hypothalamus plays a central role in the integrated regulation of energy homeostasis and body \*\*\*weight\*\*\* , and a number of hypothalamic neuropeptides, for example NPY, galanin, corticotrophin releasing factor (CRF), have been implicated in the mediation of these effects. Additionally, when melanin-concentrating hormone ( \*\*\*MCH\*\*\* ) was injected into the lateral ventricles of rats, their food consumption increased suggesting that \*\*\*MCH\*\*\* participates in the hypothalamic regulation of feeding behavior; this increase in food consumption was similar to that seen after galanin. . .  
SUMM . . . a result of abnormal control of feeding behavior, thereby establishing a role for this receptor in the serotonergic control of \*\*\*appetite\*\*\* . [L. H. Tecott et al., Nature 374: 542-546 (1995)]. A 5-HT.sub.2C agonists would therefore be useful for inhibiting food intake.. . .  
SUMM . . . fats, provides effective therapy for treating obesity and diabetes. More specifically, a combination of a .beta..sub.3 agonist and a NPY5 \*\*\*antagonist\*\*\* is particularly preferred for the treatment of obesity and diabetes.  
SUMM (a) the metabolic rate modifying agent is selected from a .beta..sub.3 agonist, leptin, or a derivative thereof, a NPY1 \*\*\*antagonist\*\*\* , a NPY4 \*\*\*antagonist\*\*\* , a UCP1, UCP2 or UCP3 activating agent, Ergoset, a CRF agonist, an agent that inhibits the activity of a

specific. . .

SUMM (b) the feeding behavior modifying agent is selected from a NPY5 \*\*\*antagonist\*\*\*, leptin or a derivative thereof, a serotonin reuptake inhibitor, a \*\*\*MCH\*\*\* \*\*\*antagonist\*\*\*, a GLP-1 agonist, a 5-HT.sub.2C agonist, a 5-HT.sub.2A agonist, a galanin \*\*\*antagonist\*\*\*, a CRF agonist, a urocortin agonist, a melanocortin agonist, an enterostatin agonist, a CCK agonist, Cimetidine, a CCK secretagogue, Ergoset. . . Sibutramine. Preferably, the metabolic rate modifying agent is selected from a .beta..sub.3 agonist, leptin, or a derivative thereof, a NPY1 \*\*\*antagonist\*\*\*, a NPY4 \*\*\*antagonist\*\*\* or a UCP1, UCP2 or UCP3 activating agent; and the feeding behavior modifying agent is selected from a NPY5 \*\*\*antagonist\*\*\*, leptin or a derivative thereof, a serotonin reuptake inhibitor, a \*\*\*MCH\*\*\* \*\*\*antagonist\*\*\*, a GLP-1 agonist, a 5-HT.sub.2C agonist, a 5-HT.sub.2A agonist, a galanin \*\*\*antagonist\*\*\*, a CRF agonist, a urocortin agonist, a melanocortin agonist or an enterostatin agonist.

SUMM In a subclass of the invention is the composition wherein the feeding behavior modifying agent is a NPY5 \*\*\*antagonist\*\*\*.

SUMM . . . the invention is the composition wherein the metabolic rate modifying agent is selected from a .beta..sub.3 agonist and a NPY1 \*\*\*antagonist\*\*\*. Preferably, the metabolic rate modifying agent is a .beta..sub.3 agonist. Most preferably, the metabolic rate modifying agent is (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(3-cyclopentylpropyl)-5-tetrazolon-1-yl]benzenesulfonamide; or. . .

SUMM An illustration of the invention is the composition wherein the metabolic rate modifying agent is a NPY1 \*\*\*antagonist\*\*\*.

SUMM Exemplifying the invention is the composition which comprises leptin, or

a derivative thereof, and a NPY5 \*\*\*antagonist\*\*\*; and the pharmaceutically acceptable salts and esters thereof.

SUMM (a) the metabolic rate increasing agent is selected from a 3 agonist, leptin, or a derivative thereof, a NPY1 \*\*\*antagonist\*\*\*, a NPY4 \*\*\*antagonist\*\*\* or a UCP1, UCP2 or UCP3 activating agent; and

SUMM (b) the feeding behavior inhibiting agent is selected from a NPY5 \*\*\*antagonist\*\*\*, leptin or a derivative thereof, a serotonin reuptake inhibitor, a \*\*\*MCH\*\*\* \*\*\*antagonist\*\*\*, a GLP-1 agonist, a 5-HT.sub.2C agonist, a 5-HT.sub.2A agonist, a galanin \*\*\*antagonist\*\*\*, a CRF agonist, a urocortin agonist, or a CCK \*\*\*antagonist\*\*\*, a melanocortin agonist or an enterostatin agonist.

SUMM Preferably, the feeding behavior inhibiting agent is a NPY5 \*\*\*antagonist\*\*\* and the metabolic rate increasing agent is selected from .beta..sub.3 agonist and a NPY \*\*\*antagonist\*\*\*. More preferably, the metabolic rate increasing agent is a .beta..sub.3 agonist. Most preferably, the metabolic rate increasing agent is (R)-N-[4-[2-[[2-hydroxy-2-(pyridin-3-yl)ethyl]amino]ethyl]phenyl]-4-[4-(3-cyclopentylpropyl)-5-tetrazolon-1-yl]benzenesulfonamide.

SUMM . . . thereof, for the treatment of obesity and diabetes. Obesity and diabetes mellitus are often treated by encouraging patients to lose \*\*\*weight\*\*\* by reducing their food intake and by increasing their metabolic rate. However, agents that reduce feed intake (e.g., leptin, leptin agonists, 5-HT.sub.2A agonists, 5-HT.sub.2C agonists, serotonin reuptake inhibitors, NPY5 \*\*\*antagonists\*\*\*, CCK agonists, GLP-1 agonists, galanin \*\*\*antagonists\*\*\*, glucagon agonists, \*\*\*MCH\*\*\* agonists) often do not have sustained effects on \*\*\*weight\*\*\* reduction. Thus, it has now been found that combination treatment with an agent that reduces feed intake with an agent that increases metabolic rate (e.g., .beta..sub.3 selective agonist, NPY1 \*\*\*antagonist\*\*\*, leptin, leptin agonist, NPY4 \*\*\*antagonist\*\*\*) is advantageous over treatment with either agent alone in the treatment of obesity and diabetes.

SUMM The term "selective," as used herein in reference to an agonist or \*\*\*antagonist\*\*\* of a specified receptor subtype, refers to an agonist or \*\*\*antagonist\*\*\* which binds to the specified receptor subtype with at least ten-fold greater affinity than it binds to other subtypes of. . .

SUMM . . . agent and a feeding behavior inhibiting agent. Most preferably, the combination comprises a selective .beta..sub.3 agonist and an NPY Y5 \*\*\*antagonist\*\*\*.

SUMM Examples of metabolic rate modifying agents include, but are not limited

to, .beta..sub.3 agonists, NPY1 \*\*\*antagonists\*\*\*, NPY4 \*\*\*antagonists\*\*\*, leptin, leptin agonists, and uncoupling protein ("UCP") activating agents, specifically UCP1, UCP2 and/or UCP3 activating agents. Although leptin is typically. . .

SUMM . . . of identifying ligands which bind to the Y1 receptor are described in WO 93/09227, published May 13, 1993. Moreover, NPY1 \*\*\*antagonists\*\*\* and their use in the diagnosis and treatment of feeding disorders are described in WO 96/14307, published May 17, 1996. The NPY1 \*\*\*antagonist\*\*\* compounds described in WO 96/14307 are preferred as metabolic rate modifying agents in the compositions and methods of the present invention. Additional NPY Y1 \*\*\*antagonist\*\*\* compounds useful as metabolic rate modifying agents are described in U.S. Pat. No. 5,554,621, EP 0 747 356 A1, EP. . . and in WO 95/17960, published Jul. 6, 1995. Thus, one of ordinary skill in the art could readily identify NPY4 \*\*\*antagonists\*\*\* useful as metabolic rate modifying agents in the compositions and methods of the present invention.

SUMM . . . leptin agonists 5-HT.sub.2A agonists, 5-HT.sub.2C agonists, serotonin reuptake inhibitors (e.g., dextroamphetamine marketed under the brand name Redux by Servier/Interneuron), NPY5 \*\*\*antagonists\*\*\*, CCK agonists (e.g., FPL-15849: Fisons, Rhone-Poulenc Rorer), GLP-1 agonists, \*\*\*MCH\*\*\* agonists, galanin \*\*\*antagonists\*\*\*, glucagon agonists, Cimetidine (Tagamet, SmithKline Beecham), Ergoset, Subutramine, urocortin agonists [see, M. Spina, et al., Science, 273, Sep. 13, 1996, . . . Lin, L. et al., Peptides 1997, 18(5): 657-661, describing the effect of enterostatin in chronically reducing fat intake and body \*\*\*weight\*\*\* in rats]. Preferably the feeding behavior modifying agent is selected from a NPY5 \*\*\*antagonist\*\*\* or leptin, or a derivative thereof.

SUMM . . . Jun. 6, 1996. One of ordinary skill in the art, following the teaching of WO 96/16542, could readily identify NPY5 \*\*\*antagonist\*\*\* compounds useful in the compositions and methods of the present invention. NPY Y5 \*\*\*antagonists\*\*\* and their use in the diagnosis and treatment of feeding disorders are described in WO 97/19682, WO 97/20820, WO 97/20821, . . .

SUMM . . . or single combination forms. For example, in a two-component combination which is the .beta..sub.3 agonist, Compound A, and a NPY5 \*\*\*antagonist\*\*\*, treatment with the NPY5 \*\*\*antagonist\*\*\* can commence prior to, subsequent to or concurrent with commencement of treatment with Compound A. Furthermore, the term administering also encompasses the use of prodrugs of the .beta..sub.3 agonist and/or NPY5 \*\*\*antagonist\*\*\* which convert in vivo to a selective .beta..sub.3 agonist or NPY5 \*\*\*antagonist\*\*\*. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the. . .

SUMM . . . compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the \*\*\*weight\*\*\* of the unit. The amount of active ingredients in such therapeutically useful compositions is such that an effective dosage will. . .

SUMM . . . utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, \*\*\*weight\*\*\*, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the. . .

SUMM . . . rate modifying agent is administered at a daily dosage of from about 0.001 to about 20 mg/kg of animal body \*\*\*weight\*\*\*, preferably given in a single dose or in divided doses two to six times a day, or in sustained release. . . behavior modifying agent is administered at a daily dosage of from about 0.001 to about 20 mg/kg of animal body \*\*\*weight\*\*\*, preferably given in a single dose or in divided doses two to six times a day, or in sustained release. . .

SUMM . . . is administered at a daily dosage of from about 0.001 milligram to about 20 milligram per kilogram of animal body \*\*\*weight\*\*\*, preferably given in a single dose or in divided doses two to six times a day, or in sustained release. . . release form. Preferably, the daily dosage of Ob protein is from about 0.05 mg/kg to about 5 mg/kg. The NPY5

\*\*\*antagonist\*\*\* is administered at a daily dosage of from about 0.001 mg/kg to about 20 mg/kg, preferably given in a single. . . a day, or in sustained release form; in the case of an adult human, the total daily dose of NPY5 \*\*\*antagonist\*\*\* will generally be from about 0.07 milligrams to about 3500 milligrams. The NPY1 \*\*\*antagonist\*\*\*

is administered at a daily dosage of from about 0.001 mg/kg to about 20 mg/kg, preferably given in a single. . . a day, or in sustained release form; in the case of an adult human, the total daily dose of NPY1 \*\*\*antagonist\*\*\* will generally be from about 0.07 milligrams to about 3500 milligrams. The dosage regimen of any of the individual components. . . the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body \*\*\*weight\*\*\*, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition. . .

SUMM . . . A is administered at a daily dosage of from 0.01 milligram to about 20 milligrams per kilogram of animal body \*\*\*weight\*\*\*, preferably given in a single dose or in divided doses two to six times a day, or in sustained release. . . constant infusion. Preferably, the daily dosage of Ob protein is from about 0.05 mg/kg to about 5 mg/kg. The NPY5 \*\*\*antagonist\*\*\* is administered at a daily dosage of from about 0.001 mg/kg to about 20 mg/kg, preferably given in a single. . . a day, or in sustained release form; in the case of an adult human, the total daily dose of NPY5 \*\*\*antagonist\*\*\* will generally be from about 0.07 milligrams to about 3500 milligrams. The NPY1 \*\*\*antagonist\*\*\* is administered at a daily dosage of from about 0.001 mg/kg to about 20 mg/kg, preferably given in a single. . . a day, or in sustained release form; in the case of an adult human, the total daily dose of NPY1 \*\*\*antagonist\*\*\* will generally be from about 0.07 milligrams to about 3500 milligrams. The dosage regimen of any of the components of. . . the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body \*\*\*weight\*\*\*, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition. . .

DETD . . . g, horseradish peroxidase linked F(ab')<sub>2</sub> fragment, Amersham) was used at 1:3000 dilution. A single immunoreactive protein with an apparent molecular \*\*\*weight\*\*\* of 14.5 kDa was identified. DETD . . . as a molecule that inhibits feed intake such as a selective serotonin 5HT2C receptor subtype agonist, an NPY5 selective receptor \*\*\*antagonist\*\*\*, a galanin \*\*\*antagonist\*\*\*, a CCK agonist, an \*\*\*MCH\*\*\* \*\*\*antagonist\*\*\*, a CRF agonist, a urocortin agonist, a glucagon-like peptide agonist, a glucagon agonist, leptin, leptin agonist. Compound C is a compound that increases metabolic rate such as a selective beta-3 adrenergic receptor agonist (e.g., Compound A), an NPY1 receptor \*\*\*antagonist\*\*\*, leptin, leptin agonist. Human patients are given by injection (i.e., subcutaneous, intramuscular or intravenous) or orally of 0.001 to 100. . . are treated daily for a six month period. A set of control patients are untreated (e.g., placebo) for comparison. Body \*\*\*weight\*\*\* data are collected each week and a sustained decrease in body \*\*\*weight\*\*\* of at least 2% is

<-----User Break----->

u  
=>  
=> d his

(FILE 'HOME' ENTERED AT 11:59:19 ON 13 SEP 2000)

FILE 'USPATFULL' ENTERED AT 11:59:25 ON 13 SEP 2000  
L1 571 S MCH OR MELANOCYTE CONCENTRATING HORMONE  
L2 45 S L1 AND ANTAGONI?  
L3 44 S L2 AND WEIGHT  
L4 3120 S L3 AND EAT? OR APPETITE  
L5 7 S L3 AND (EAT? OR APPETITE)

=> s (mch or melanocyte concentrating hormone) (3a) antagonis? (3a) (weight or eat? or appetite)

571 MCH  
752 MELANOCYTE  
31634 CONCENTRATING  
19149 HORMONE  
1 MELANOCYTE CONCENTRATING HORMONE  
(MELANOCYTE(W)CONCENTRATING(W)HORMONE)  
25083 ANTAGONIS?

859860 WEIGHT  
18954 EAT?  
3116 APPETITE  
L6 0 (MCH OR MELANOCYTE CONCENTRATING HORMONE)  
(3A) ANTAGONIS? (3A)  
(WEIGHT OR EAT? OR APPETITE)

=> s (mch or melanocyte concentrating hormone) p antagonis? p (weight or eat? or appetite)

MISSING OPERATOR HORMONE) P ANTAGONIS

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> d his

(FILE 'HOME' ENTERED AT 11:59:19 ON 13 SEP 2000)

FILE 'USPATFULL' ENTERED AT 11:59:25 ON 13 SEP 2000  
L1 571 S MCH OR MELANOCYTE CONCENTRATING HORMONE  
L2 45 S L1 AND ANTAGONI?  
L3 44 S L2 AND WEIGHT  
L4 3120 S L3 AND EAT? OR APPETITE  
L5 7 S L3 AND (EAT? OR APPETITE)  
L6 0 S (MCH OR MELANOCYTE CONCENTRATING HORMONE)  
(3A) ANTAGONIS? (3A)

=> s l1 p l2 p (weight or appetite)

MISSING OPERATOR L1 P L2

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 (5a) l2 (5a) (weight or appetite)

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'L1 (5A) L2'  
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'L2 (5A)'

859860 WEIGHT  
3116 APPETITE  
L7 44 L1 (5A) L2 (5A) (WEIGHT OR APPETITE)

=> d his

(FILE 'HOME' ENTERED AT 11:59:19 ON 13 SEP 2000)

FILE 'USPATFULL' ENTERED AT 11:59:25 ON 13 SEP 2000  
L1 571 S MCH OR MELANOCYTE CONCENTRATING HORMONE  
L2 45 S L1 AND ANTAGONI?  
L3 44 S L2 AND WEIGHT  
L4 3120 S L3 AND EAT? OR APPETITE  
L5 7 S L3 AND (EAT? OR APPETITE)  
L6 0 S (MCH OR MELANOCYTE CONCENTRATING HORMONE)  
(3A) ANTAGONIS? (3A)  
L7 44 S L1 (5A) L2 (5A) (WEIGHT OR APPETITE)

=> s l7 not l5

L8 37 L7 NOT L5

=> d l-

YOU HAVE REQUESTED DATA FROM 37 ANSWERS - CONTINUE?  
Y/(N):y

L8 ANSWER 1 OF 37 USPATFULL  
AN 2000:84319 USPATFULL

TI Sulfonamide substituted aspartic acid interleukin-1.beta. converting enzyme inhibitors  
IN Allen, Hamish John, Boylston, MA, United States  
Brady, Kenneth Dale, Worcester, MA, United States  
Harter, William Glen, Chelsea, MI, United States  
Lunney, Elizabeth Ann, Ann Arbor, MI, United States  
Plummer, Mark Stephen, Dexter, MI, United States  
Sawyer, Tomi, Southborough, MA, United States  
Shahripour, Aurash, Ann Arbor, MI, United States  
Walker, Nigel, Dossenheim, Germany, Federal Republic of  
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)  
PI US 6083981 20000704  
WO 9816504 19980423  
AI US 1999-284425 19990409 (9)  
WO 1997-US18406 19971009  
19990409 PCT 371 date  
19990409 PCT 102(e) date  
PRAI US 1996-28323 19961011 (60)  
DT Utility  
LN.CNT 1419  
INCL INCLM: 514/471.000  
INCLS: 549/479.000; 549/528.000; 549/562.000; 549/563.000;  
560/012.000;  
560/013.000; 562/430.000  
NCL NCLM: 514/471.000  
NCLS: 549/479.000; 549/528.000; 549/562.000; 549/563.000;  
560/012.000;  
560/013.000; 562/430.000  
IC [7]  
ICM: A61K031-341  
ICS: C07D307-40  
EXF 514/528; 514/562; 514/563; 514/471; 560/12; 560/13; 562/430;  
549/479  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 37 USPATFULL  
AN 2000:77037 USPATFULL  
TI Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients  
IN Storkus, Walter J., Glenshaw, PA, United States  
Lotze, Michael T., Pittsburgh, PA, United States  
PA University of Pittsburgh, Pittsburgh, PA, United States (U.S. corporation)  
PI US 6077519 20000620  
AI US 1997-785831 19970115 (8)  
RLI Continuation-in-part of Ser. No. US 1995-474120, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1993-11007, filed on 29 Jan 1993, now abandoned  
DT Utility  
LN.CNT 3161  
INCL INCLM: 424/277.100  
INCLS: 424/085.100; 424/093.710; 435/070.100; 435/070.300;  
435/325.000;  
435/372.000; 435/384.000; 435/385.000; 435/386.000; 514/002.000;  
514/021.000; 530/344.000  
NCL NCLM: 424/277.100  
NCLS: 424/085.100; 424/093.710; 435/070.100; 435/070.300;  
435/325.000;  
435/372.000; 435/384.000; 435/385.000; 435/386.000; 514/002.000;  
514/021.000; 530/344.000  
IC [7]  
ICM: A61K035-12  
ICS: A61K038-00; C12N015-85; C07K005-00  
EXF 424/277.1; 424/85.1; 424/93.71; 435/70.1; 435/70.3; 435/325;  
435/372;  
435/384; 435/385; 435/386; 514/2; 514/21; 530/344  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 37 USPATFULL  
AN 2000:47216 USPATFULL

TI Cloning and characterizing of genes associated with long-term memory  
IN Tully, Timothy P., Cold Spring Harbor, NY, United States  
Yin, Jerry Chi-Ping, Huntington, NY, United States  
PA Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States (U.S. corporation)  
PI US 6051559 20000418  
AI US 1994-361063 19941221 (8)  
RLI Continuation-in-part of Ser. No. US 1994-319866, filed on 7 Oct 1994  
DT Utility  
LN.CNT 4642  
INCL INCLM: 514/044.000  
INCLS: 514/002.000; 424/130.100  
NCL NCLM: 514/044.000  
NCLS: 424/130.100; 514/002.000  
IC [7]  
ICM: A61K039-395  
ICS: A01N037-18; A01N043-04  
EXF 536/23.1; 514/44; 514/2; 424/93.1; 424/130.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 37 USPATFULL  
AN 2000:44136 USPATFULL  
TI Lipoxin compounds and their use in treating cell proliferative disorders  
IN Serhan, Charles N., Wellesley, MA, United States  
PA Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)  
PI US 6048897 20000411  
AI US 1996-712610 19960913 (8)  
RLI Continuation-in-part of Ser. No. US 1995-453125, filed on 31 May 1995, now patented, Pat. No. US 5648512 which is a division of Ser. No. US 1994-260030, filed on 15 Jun 1994, now patented, Pat. No. US 5441951, issued on 15 Aug 1995 which is a continuation-in-part of Ser. No. US 1993-77300, filed on 15 Jun 1993, now abandoned  
DT Utility  
LN.CNT 2924  
INCL INCLM: 514/560.000  
INCLS: 562/586.000; 562/598.000; 562/600.000  
NCL NCLM: 514/560.000  
NCLS: 562/586.000; 562/598.000; 562/600.000  
IC [7]  
ICM: A01N037-00  
ICS: C07C059-00; C07C057-02; C07C051-42  
EXF 562/586; 562/598; 562/600; 514/560  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 37 USPATFULL  
AN 2000:27584 USPATFULL  
TI Cystic fibrosis therapy  
IN Mrsny, Randall J., Redwood City, CA, United States  
Shen, Ben-Quan, San Francisco, CA, United States  
Widdicombe, Jonathan H., Lafayette, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)  
Children's Hospital Medical Center of Northern California, Oakland, CA, United States (U.S. corporation)  
PI US 6033688 20000307  
AI US 1997-923754 19970902 (8)  
RLI Division of Ser. No. US 1996-713048, filed on 12 Sep 1996, now patented,  
Pat. No. US 5855918  
PRAI US 1995-3581 19950912 (60)  
US 1996-10509 19960124 (60)  
DT Utility  
LN.CNT 873  
INCL INCLM: 424/530.000  
INCLS: 424/531.000; 424/532.000; 514/002.000; 514/021.000  
NCL NCLM: 424/530.000  
NCLS: 424/531.000; 424/532.000; 514/002.000; 514/021.000  
IC [7]

- ICM: A61K035-16  
EXF 514/2; 514/21; 424/529; 424/530; 424/531; 424/532
- L8 ANSWER 6 OF 37 USPATFULL  
AN 1999:85574 USPATFULL  
TI Cloning and characterizing of genes associated with long-term memory  
IN Tully, Timothy P., Cold Spring Harbor, NY, United States  
Yin, Jerry Chi-Ping, Huntington, NY, United States  
Regulski, Michael, Huntington, NY, United States  
PA Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States  
(U.S. corporation)  
PI US 5929223 19990727  
AI US 1994-319866 19941007 (8)  
DT Utility  
LN.CNT 3318  
INCL INCLM: 536/023.500  
INCLS: 536/023.100  
NCL NCLM: 536/023.500  
NCLS: 536/023.100  
IC [6]  
ICM: C07H021-04  
EXF 536/23.1; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
- L8 ANSWER 7 OF 37 USPATFULL  
AN 1999:75646 USPATFULL  
TI Hydroxamate inhibitors of interleukin-1.bet.a. converting enzyme  
IN Allen, Hamish John, Shrewsbury, MA, United States  
Brady, Kenneth Dale, Worcester, MA, United States  
Caprathe, Bradley William, Livonia, MI, United States  
Galatsis, Paul, Ann Arbor, MI, United States  
Gilmore, John Lodge, Ann Arbor, MI, United States  
Hays, Sheryl Jeanne, Ann Arbor, MI, United States  
Talanian, Robert Vincent, Harvard, MA, United States  
Walker, Nigel, Dossenheim, Germany, Federal Republic of  
Warmus, Joseph Scott, Ann Arbor, MI, United States  
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S.  
corporation)  
BASF Aktiengesellschaft, Ludwigshafen, Germany, Federal Republic of  
(non-U.S. corporation)  
PI US 5919790 19990706  
AI US 1997-942605 19971002 (8)  
PRAI US 1996-28324 19961011 (60)  
DT Utility  
LN.CNT 1124  
INCL INCLM: 514/278.000  
INCLS: 514/412.000; 514/416.000; 514/417.000; 514/418.000;  
514/424.000;  
514/425.000; 546/018.000; 546/122.000; 546/139.000; 546/249.000;  
548/472.000; 548/475.000; 548/486.000; 548/512.000; 548/514.000;  
548/530.000; 548/300.100; 548/146.000; 560/312.000; 562/444.000;  
544/242.000; 549/029.000; 549/049.000; 549/434.000  
NCL NCLM: 514/278.000  
NCLS: 514/412.000; 514/416.000; 514/417.000; 514/418.000;  
514/424.000;  
514/425.000; 544/242.000; 546/018.000; 546/122.000; 546/139.000;  
546/249.000; 548/146.000; 548/300.100; 548/472.000; 548/475.000;  
548/486.000; 548/512.000; 548/514.000; 548/530.000; 549/029.000;  
549/049.000; 549/434.000; 560/312.000; 562/444.000  
IC [6]  
ICM: A61K031-405  
ICS: A61K031-44; C07C259-08; C07C229-32; C07D209-34;  
C07D209-46;  
C07D209-48; C07D221-20  
EXF 514/278; 514/412; 514/416; 514/417; 514/418; 514/424; 514/425;  
546/18;  
548/475; 548/486; 548/472; 548/514; 548/512  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
- L8 ANSWER 8 OF 37 USPATFULL  
AN 1999:34025 USPATFULL
- TI Compositions and methods for treating and preventing pathologies  
including cancer  
IN Samid, Dvorit, Rockville, MD, United States  
PA The United States of America as represented by the Department of Health  
and Human Services, Washington, DC, United States (U.S. government)  
PI US 5883124 19990316  
AI US 1995-484615 19950607 (8)  
RLI Division of Ser. No. US 1994-207521, filed on 7 Mar 1994 which is a  
continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993  
which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21  
Oct 1991, now abandoned  
DT Utility  
LN.CNT 7729  
INCL INCLM: 514/538.000  
INCLS: 514/557.000; 514/563.000; 514/567.000; 514/568.000;  
514/570.000;  
514/725.000  
NCL NCLM: 514/538.000  
NCLS: 514/557.000; 514/563.000; 514/567.000; 514/568.000;  
514/570.000;  
514/725.000  
IC [6]  
ICM: A01N037-12  
ICS: A01N037-44; A61K031-24  
EXF 514/538; 514/557; 514/563; 514/567; 514/568; 514/570; 514/725  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
- L8 ANSWER 9 OF 37 USPATFULL  
AN 1999:27613 USPATFULL  
TI Pharmaceutical compositions for the treatment or prevention of disorders  
in the eye  
IN Naveh, Nava, Tel-Aviv, Israel  
PA Ramot University Authority for Applied Research and Industrial  
Development Ltd., Tel-Aviv, Israel (non-U.S. corporation)  
PI US 5877154 19990302  
AI US 1995-570813 19951212 (8)  
RLI Continuation of Ser. No. US 1993-38109, filed on 29 Mar 1993, now  
abandoned  
PRAI IL 1992-101441 19920401  
DT Utility  
LN.CNT 660  
INCL INCLM: 514/014.000  
INCLS: 530/517.000  
NCL NCLM: 514/014.000  
NCLS: 530/327.000  
IC [6]  
ICM: A61K038-00  
EXF 530/517; 514/14  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
- L8 ANSWER 10 OF 37 USPATFULL  
AN 1999:24643 USPATFULL  
TI Inhibitors of interleukin-1.bet.a. converting enzyme  
IN Batchelor, Mark James, Cumnor Hill, United Kingdom  
Bebington, David, Pewsey, United Kingdom  
Bemis, Guy W., Arlington, MA, United States  
Fridman, Wolf Herman, Paris, France  
Gillespie, Roger John, Oaksey, United Kingdom  
Golec, Julian M. C., Ashbury, United Kingdom  
Lauffer, David J., Stow, MA, United States  
Livingston, David J., Newtonville, MA, United States  
Matharu, Saroop Singh, Cricklade, United Kingdom  
Mullican, Michael D., Needham, MA, United States  
Murcko, Mark A., Holliston, MA, United States  
Murdoch, Robert, Highworth, United Kingdom  
Zelle, Robert E., Stow, MA, United States  
PA Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States  
(U.S.  
corporation)  
PI US 5874424 19990223  
AI US 1996-598332 19960208 (8)

RLI Continuation-in-part of Ser. No. US 1995-575641, filed on 20 Dec 1995  
DT Utility  
LN.CNT 7430  
INCL INCLM: 514/221.000  
INCLS: 514/211.000; 514/220.000; 540/491.000; 540/495.000;  
540/500.000;  
540/501.000  
NCL NCLM: 514/221.000  
NCLS: 514/211.000; 514/211.150; 514/217.030; 514/220.000;  
540/491.000;  
540/495.000; 540/500.000; 540/501.000  
IC [6]  
ICM: A61K031-55  
ICS: C07D243-02  
EXF 540/500; 514/221  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 11 OF 37 USPATFULL  
AN 1999:1259 USPATFULL  
TI Cystic fibrosis therapy  
IN Mrsny, Randall J., Redwood City, CA, United States  
Shen, Ben-Quan, San Francisco, CA, United States  
Widdicombe, Jonathan H., Lafayette, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
Children's Hospital Medical Center of Northern California, Oakland, CA,  
United States (U.S. corporation)  
Regents of the University of CA, Oakland, CA, United States (U.S.  
corporation)  
PI US 5855918 19990105  
AI US 1996-713048 19960912 (8)  
PRAI US 1995-3581 19950912 (60)  
US 1996-10509 19960124 (60)  
DT Utility  
LN.CNT 874  
INCL INCLM: 424/530.000  
INCLS: 424/531.000; 424/532.000; 514/002.000; 514/021.000  
NCL NCLM: 424/530.000  
NCLS: 424/531.000; 424/532.000; 514/002.000; 514/021.000  
IC [6]  
ICM: A61K035-16  
EXF 514/2; 514/21; 424/530; 424/531; 424/532

L8 ANSWER 12 OF 37 USPATFULL  
AN 1998:159986 USPATFULL  
TI Phenylacetate and derivatives alone or in combination with other  
compounds against neoplastic conditions and other disorders  
IN Samid, Dvorit, Rockville, MD, United States  
PA The United States of America as represented by the Department of Health  
and Human Services, Washington, DC, United States (U.S. government)  
PI US 5852056 19981222  
WO 9510271 19950420  
AI US 1996-633833 19960410 (8)  
WO 1994-US11492 19941012  
19960410 PCT 371 date  
19960410 PCT 102(e) date  
RLI Continuation of Ser. No. US 1994-207521, filed on 7 Mar 1994, now  
patented, Pat. No. US 5605930 And Ser. No. US 1993-135661, filed on 12  
Oct 1993, now patented, Pat. No. US 5635532 , each Ser. No. US - which  
is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct  
1991, now abandoned  
DT Utility  
LN.CNT 5051  
INCL INCLM: 514/510.000  
INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000;  
514/563.000;  
514/567.000  
NCL NCLM: 514/510.000  
NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000;  
514/563.000;  
514/567.000

IC [6]  
ICM: A01N037-12  
ICS: A01N037-44; A61K031-195; A61K031-24  
EXF 514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 13 OF 37 USPATFULL  
AN 1998:159748 USPATFULL  
TI MCH4 and MCH5, apoptotic proteases  
IN Alnemri, Emad S., Ambler, PA, United States  
Fernandes-Alnemri, Teresa, Ambler, PA, United States  
Litwack, Gerald, Wynnewood, PA, United States  
Armstrong, Robert, San Diego, CA, United States  
Tomaselli, Kevin, La Jolla, CA, United States  
PA IDUN Pharmaceuticals, Inc., La Jolla, CA, United States (U.S.  
corporation)  
PI US 5851815 19981222  
AI US 1996-618408 19960319 (8)  
DT Utility  
LN.CNT 1800  
INCL INCLM: 435/219.000  
INCLS: 435/183.000; 435/212.000; 530/324.000  
NCL NCLM: 435/219.000  
NCLS: 435/183.000; 435/212.000; 530/324.000  
IC [6]  
ICM: C12N009-50  
ICS: C12N009-48; A61K038-00  
EXF 435/183; 435/212; 435/219; 530/324  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 14 OF 37 USPATFULL  
AN 1998:157338 USPATFULL  
TI Isoxazoline and isoxazole fibrinogen receptor \*\*\*antagonists\*\*\*  
IN Witayak, John, West Grove, PA, United States  
Xue, Chu-Biao, Hockessin, DE, United States  
Sielecki-Dzurdz, Thais Motria, Newark, DE, United States  
Olson, Richard Eric, Wilmington, DE, United States  
Degrado, William Frank, Moylan, PA, United States  
Cain, Gary Avonn, Wilmington, DE, United States  
Batt, Douglas Guy, Wilmington, DE, United States  
Pinto, Donald, Newark, DE, United States  
Hussain, Munir Alwan, Wilmington, DE, United States  
Mousa, Shaker Ahmed, Lincoln University, PA, United States  
PA The DuPont Merck Pharmaceutical Company, Wilmington, DE, United  
States  
(U.S. corporation)  
PI US 5849736 19981215  
AI US 1995-4545436 19950531 (8)  
RLI Continuation-in-part of Ser. No. US 1994-337920, filed on 10 Nov 1994,  
now abandoned which is a continuation-in-part of Ser. No. US  
1994-232961, filed on 22 Apr 1994, now abandoned which is a  
continuation-in-part of Ser. No. US 1993-157598, filed on 24 Nov 1993,  
now abandoned  
DT Utility  
LN.CNT 11841  
INCL INCLM: 514/227.800  
INCLS: 514/236.800; 514/269.000; 514/307.000; 514/326.000;  
514/340.000;  
514/365.000; 514/378.000; 514/379.000; 514/380.000; 544/060.000;  
544/111.000; 544/137.000; 544/140.000; 544/297.000; 544/298.000;  
544/322.000; 544/333.000; 546/141.000; 546/143.000; 546/209.000;  
546/275.000; 548/146.000; 548/240.000; 548/245.000; 548/248.000  
NCL NCLM: 514/227.800  
NCLS: 514/236.800; 514/269.000; 514/307.000; 514/310.000;  
514/326.000;  
514/340.000; 514/365.000; 514/378.000; 514/379.000; 514/380.000;  
544/060.000; 544/111.000; 544/137.000; 544/140.000; 544/297.000;  
544/298.000; 544/322.000; 544/333.000; 546/015.000; 546/141.000;  
546/143.000; 546/209.000; 546/275.400; 548/146.000; 548/240.000;  
548/245.000; 548/248.000

IC [6]

ICM: C07D261-02  
ICS: C07D217-00; A61K031-54; A61K031-445  
EXF 548/240; 548/248; 548/245; 548/146; 546/275; 546/204; 546/141;  
546/143;  
546/146; 544/137; 544/140; 544/111; 544/60; 544/297; 544/298;  
544/322;  
544/333; 514/326; 514/340; 514/378; 514/379; 514/380; 514/227.8;  
514/236.8; 514/269; 514/307; 514/310; 514/365  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 15 OF 37 USPATFULL  
AN 1998:150994 USPATFULL

TI Compositions and methods for treating and preventing pathologies including cancer  
IN Samid, Dvorit, Rockville, MD, United States  
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
PI US 5843994 19981201  
AI US 1995-478264 19950607 (8)  
RLI Division of Ser. No. US 1994-207521, filed on 7 Mar 1994, now patented,  
Pat. No. US 5605930 which is a continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991, now abandoned

DT Utility  
LN.CNT 7935  
INCL INCLM: 514/510.000  
INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000;  
514/563.000;  
514/567.000  
NCL NCLM: 514/510.000  
NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000;  
514/563.000;  
514/567.000

IC [6]  
ICM: A61K031-21  
ICS: A01N047-40  
EXF 514/510; 514/513; 514/515; 514/529; 514/538; 514/563; 514/567  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 16 OF 37 USPATFULL

AN 1998:150907 USPATFULL

TI Inhibitors of interleukin-1.beta.converting enzyme  
IN Bemis, Guy W., Arlington, MA, United States  
Duffy, John P., Brighton, MA, United States  
Fridman, Wolf Herman, Paris, France  
Golec, Julian M. C., Ashbury, United Kingdom  
Livingston, David J., Newtonville, MA, United States  
Mullican, Michael D., Needham, MA, United States  
Murcko, Mark A., Holliston, MA, United States  
Zelle, Robert E., Stow, MA, United States

PA Vertex Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)  
PI US 5843904 19981201  
AI US 1995-575648 19951220 (8)

DT Utility  
LN.CNT 1826  
INCL INCLM: 514/018.000  
INCLS: 514/019.000; 530/331.000; 530/330.000  
NCL NCLM: 514/018.000  
NCLS: 514/019.000; 530/330.000; 530/331.000  
IC [6]  
ICM: A61K038-00  
EXF 530/331; 530/330; 514/18; 514/19  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 17 OF 37 USPATFULL

AN 1998:9533 USPATFULL

TI Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using

phenylacetic acids and derivatives thereof

IN Samid, Dvorit, Rockville, MD, United States  
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
PI US 5712307 19980127  
AI US 1995-465924 19950606 (8)  
RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
DT Utility  
LN.CNT 4169  
INCL INCLM: 514/538.000  
INCLS: 514/563.000; 514/567.000  
NCL NCLM: 514/538.000  
NCLS: 514/563.000; 514/567.000  
IC [6]  
ICM: A01N037-12  
ICS: A01N037-44; A61K031-24  
EXF 514/538; 514/563; 514/567  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 18 OF 37 USPATFULL

AN 1998:7096 USPATFULL

TI Compositions and methods for therapy and prevention of pathologies including cancer, AIDS, and anemia

IN Samid, Dvorit, Rockville, VA, United States  
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
PI US 5710178 19980120  
AI US 1995-469691 19950606 (8)  
RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
DT Utility  
LN.CNT 4261  
INCL INCLM: 514/557.000  
INCLS: 514/568.000; 514/570.000  
NCL NCLM: 514/557.000  
NCLS: 514/568.000; 514/570.000  
IC [6]  
ICM: A01N037-00  
ICS: A61K031-19  
EXF 514/557; 514/568; 514/570; 562/405; 562/493; 562/511; 562/473;  
562/490  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 19 OF 37 USPATFULL

AN 1998:4624 USPATFULL

TI Methods for promoting wound healing

IN Samid, Dvorit, Rockville, MD, United States  
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
PI US 5708025 19980113  
AI US 1995-465835 19950606 (8)  
RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
DT Utility  
LN.CNT 4206  
INCL INCLM: 514/538.000  
INCLS: 514/563.000; 514/567.000; 514/885.000; 514/886.000;  
514/928.000  
NCL NCLM: 514/538.000  
NCLS: 514/563.000; 514/567.000; 514/885.000; 514/886.000;  
514/928.000  
IC [6]  
ICM: A01N037-12  
ICS: A01N037-44; A61K031-24  
EXF 514/538; 514/563; 514/567; 514/885; 514/886; 514/928; 560/19  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 20 OF 37 USPATFULL

AN 97:76161 USPATFULL

TI Methods for treating neoplastic conditions using phenylacetic acid and

derivatives thereof  
 IN Samid, Dvorit, Rockville, MD, United States  
 PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
 PI US 5661179 19970826  
 AI US 1995-469466 19950606 (8)  
 RLI Continuation of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991, now abandoned  
 DT Utility  
 LN.CNT 4056  
 INCL INCLM: 514/538.000  
 INCLS: 514/563.000; 514/567.000; 560/019.000  
 NCL NCLM: 514/538.000  
 NCLS: 514/563.000; 514/567.000; 560/019.000  
 IC [6]  
 ICM: A01N037-12  
 ICS: A01N037-44  
 EXF 514/538; 514/563; 514/567; 560/19  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 21 OF 37 USPATFULL  
 AN 97:68500 USPATFULL  
 TI Methods for prevention of cancer using phenylacetic acids and derivatives thereof  
 IN Samid, Dvorit, Rockville, MD, United States  
 PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
 PI US 5654333 19970805  
 AI US 1995-465941 19950606 (8)  
 RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
 DT Utility  
 LN.CNT 4088  
 INCL INCLM: 514/538.000  
 INCLS: 514/563.000; 514/567.000  
 NCL NCLM: 514/538.000  
 NCLS: 514/563.000; 514/567.000  
 IC [6]  
 ICM: A01N037-12  
 ICS: A01N037-44; A61K031-24  
 EXF 514/538; 514/563; 514/567  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 22 OF 37 USPATFULL  
 AN 97:61839 USPATFULL  
 TI Lipoxin compounds  
 IN Serhan, Charles N., Boston, MA, United States  
 PA Brigham & Womens Hospital, Boston, MA, United States (U.S. corporation)  
 PI US 5648512 19970715  
 AI US 1995-453125 19950531 (8)  
 RLI Division of Ser. No. US 1994-260030, filed on 15 Jun 1994, now patented, Pat. No. US 5441951 which is a continuation-in-part of Ser. No. US 1993-77300, filed on 15 Jun 1993, now abandoned  
 DT Utility  
 LN.CNT 2197  
 INCL INCLM: 560/009.000  
 INCLS: 560/019.000; 560/103.000; 560/187.000; 562/587.000  
 NCL NCLM: 560/009.000  
 NCLS: 560/019.000; 560/103.000; 560/187.000; 562/587.000  
 IC [6]  
 ICM: C07C321-08  
 ICS: C07C069-66; C07C059-105  
 EXF 560/103; 560/9; 560/19; 560/187; 562/587  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 23 OF 37 USPATFULL  
 AN 97:47438 USPATFULL

TI Methods for inducing differentiation of a cell using phenyacetic acid and derivatives  
 IN Samid, Dvorit, Rockville, MD, United States  
 PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
 PI US 5635533 19970603  
 AI US 1995-470229 19950606 (8)  
 RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
 DT Utility  
 LN.CNT 4108  
 INCL INCLM: 514/538.000  
 INCLS: 514/563.000; 514/567.000  
 NCL NCLM: 514/538.000  
 NCLS: 514/563.000; 514/567.000  
 IC [6]  
 ICM: A01N037-12  
 ICS: A01N037-44; A61K031-24  
 EXF 514/538; 514/563; 514/567  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 24 OF 37 USPATFULL  
 AN 97:47437 USPATFULL  
 TI Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia  
 IN Samid, Dvorit, Rockville, MD, United States  
 PA The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
 PI US 5635532 19970603  
 AI US 1993-135661 19931012 (8)  
 RLI Continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
 DT Utility  
 LN.CNT 4105  
 INCL INCLM: 514/538.000  
 INCLS: 514/563.000; 514/567.000; 560/019.000  
 NCL NCLM: 514/538.000  
 NCLS: 514/563.000; 514/567.000; 560/019.000  
 IC [6]  
 ICM: A01N037-12  
 ICS: A01N037-44; A61K031-195; A61K031-24  
 EXF 514/538; 514/563; 514/567; 560/19  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 25 OF 37 USPATFULL  
 AN 97:40765 USPATFULL  
 TI Homeopathic dilutions of growth factors  
 IN Brewitt, Barbara, 5557 - 36th Ave. NE, Seattle, WA, United States 98105-2313  
 PI US 5629286 19970513  
 AI US 1996-710040 19960910 (8)  
 RLI Continuation of Ser. No. US 1995-488722, filed on 8 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-221365, filed on 31 Mar 1994, now abandoned  
 DT Utility  
 LN.CNT 1409  
 INCL INCLM: 514/002.000  
 INCLS: 530/351.000; 530/303.000  
 NCL NCLM: 514/002.000  
 NCLS: 530/303.000; 530/351.000  
 IC [6]  
 ICM: A01N037-18  
 EXF 604/890.1; 128/907; 530/350; 530/351; 530/300-303; 514/2; 514/3  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 26 OF 37 USPATFULL  
 AN 97:16085 USPATFULL  
 TI Compositions and methods for treating and preventing pathologies including cancer  
 IN Samid, Dvorit, Rockville, MD, United States  
 PA The United States of America as represented by the Department of Health

and Human Services, Washington, DC, United States (U.S. government)  
PI US 5605930 19970225  
AI US 1994-207521 19940307 (8)  
RLI Continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993  
which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21  
Oct 1991  
DT Utility  
LN.CNT 7722  
INCL INCLM: 514/510.000  
INCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000;  
514/563.000;  
514/567.000  
NCL NCLM: 514/510.000  
NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000;  
514/563.000;  
514/567.000  
IC [6]  
ICM: A61K031-21  
ICS: A01N037-00; A01N047-40; A01N047-46  
EXF 514/538; 514/563; 514/567; 514/510; 514/513; 514/515; 514/529  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 27 OF 37 USPATFULL  
AN 96:72899 USPATFULL  
TI Imidazole 5-position substituted angiotensin II \*\*\*antagonists\*\*\*  
IN Duncia, John J. V., Wilmington, DE, United States  
Ensinger, Carol L., Newark, DE, United States  
Olson, Richard E., Wilmington, DE, United States  
Quan, Mimi L., Newark, DE, United States  
Santella, III, Joseph B., Springfield, PA, United States  
Vanatten, Mary K., Wilmington, DE, United States  
PA The DuPont Merck Pharmaceutical Company, Wilmington, DE, United  
States  
(U.S. corporation)  
PI US 5545651 19960813  
AI US 1994-348843 19941128 (8)  
RLI Division of Ser. No. US 1993-72977, filed on 10 Jun 1993, now patented,  
Pat. No. US 5395844  
DT Utility  
LN.CNT 5010  
INCL INCLM: 514/381.000  
INCLS: 514/235.800; 514/307.000; 514/314.000; 514/326.000;  
514/333.000;  
514/341.000; 514/359.000; 514/383.000; 514/397.000; 514/398.000;  
514/399.000; 514/400.000; 544/139.000; 546/148.000; 546/174.000;  
546/176.000; 546/180.000; 546/210.000; 546/256.000; 546/272.400;  
546/272.700; 546/274.400; 546/274.700; 546/275.100; 546/022.000;  
546/023.000; 546/024.000; 548/253.000; 548/255.000; 548/261.000;  
548/266.200; 548/315.100; 548/335.100; 548/341.100; 548/343.100;  
548/343.500; 548/346.100; 548/314.700  
NCL NCLM: 514/381.000  
NCLS: 514/235.800; 514/307.000; 514/314.000; 514/326.000;  
514/333.000;  
514/341.000; 514/359.000; 514/383.000; 514/397.000; 514/398.000;  
514/399.000; 514/400.000; 544/139.000; 546/022.000; 546/023.000;  
546/024.000; 546/148.000; 546/174.000; 546/176.000; 546/180.000;  
546/210.000; 546/256.000; 546/272.400; 546/272.700; 546/274.400;  
546/274.700; 546/275.100; 548/253.000; 548/255.000; 548/261.000;  
548/266.200; 548/314.700; 548/315.100; 548/335.100; 548/341.100;  
548/343.100; 548/343.500; 548/346.100  
IC [6]  
ICM: C07D401-14  
ICS: A61K031-415  
EXF 546/207; 546/210; 546/256; 546/276; 546/148; 546/180; 546/174;  
546/176;  
548/387; 548/253; 548/315.1; 548/319.7; 548/335.1; 548/341.1;  
548/343.5;  
548/346.1; 548/255; 548/261; 548/266.2; 548/343.1; 514/326; 514/333;  
514/341; 514/381; 514/396; 514/398; 514/399; 514/400; 514/397;  
514/235.8; 514/307; 514/314; 514/383; 514/359; 544/139  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 28 OF 37 USPATFULL  
AN 96:55851 USPATFULL  
TI Peptides of melanin concentrating hormone precursor  
IN Vaughn, Joan, San Diego, CA, United States  
Fischer, Wolfgang H., Solano Beach, CA, United States  
Rivier, Jean E. F., La Jolla, CA, United States  
Nahon, Jean-Louis M., San Diego, CA, United States  
Presse, Francoise G., San Diego, CA, United States  
Vale, Jr., Wylie W., La Jolla, CA, United States  
PA The Salk Institute for Biological Studies, La Jolla, CA, United States  
(U.S. corporation)  
PI US 5530095 19960625  
AI US 1995-447613 19950523 (8)  
RLI Division of Ser. No. US 1994-208531, filed on 9 Mar 1994, now  
patented,  
Pat. No. US 5449766 which is a division of Ser. No. US 1991-733660,  
filed on 22 Jul 1991, now abandoned which is a division of Ser. No. US  
1989-326984, filed on 22 Mar 1989, now patented, Pat. No. US 5049655  
DT Utility  
LN.CNT 1458  
INCL INCLM: 530/326.000  
INCLS: 530/327.000; 530/395.000; 435/069.400  
NCL NCLM: 530/326.000  
NCLS: 435/069.400; 530/327.000; 530/395.000  
IC [6]  
ICM: C07K007-08  
ICS: C12P021-02  
EXF 530/326; 530/327; 530/395; 435/69.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 29 OF 37 USPATFULL  
AN 96:21081 USPATFULL  
TI Platelet aggregation-inhibiting peptides  
IN Sato, Yoshimi, Kawasaki, Japan  
Hayashi, Yoshio, Kawasaki, Japan  
Katada, Jun, Kawasaki, Japan  
PA Nippon Steel Corporation, Tokyo, Japan (non-U.S. corporation)  
PI US 5498601 19960312  
WO 9405696 19940317  
AI US 1994-232261 19940506 (8)  
WO 1993-JP1262 19930907  
19940506 PCT 371 date  
19940506 PCT 102(e) date  
PRAI JP 1992-238624 19920709  
JP 1993-203962 19930818  
DT Utility  
LN.CNT 2230  
INCL INCLM: 514/017.000  
INCLS: 514/008.000; 530/322.000; 530/329.000; 530/330.000  
NCL NCLM: 514/017.000  
NCLS: 514/008.000; 530/322.000; 530/329.000; 530/330.000  
IC [6]  
ICM: A61K038-04  
ICS: C07K007-00  
EXF 530/322; 530/329; 530/330; 514/8; 514/17  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 30 OF 37 USPATFULL  
AN 95:82360 USPATFULL  
TI DNA encoding NEI and NGE peptides  
IN Vaughan, Joan, San Diego, CA, United States  
Fischer, Wolfgang H., Solano Beach, CA, United States  
Rivier, Jean E. F., La Jolla, CA, United States  
Nahon, Jean-Louis M., San Diego, CA, United States  
Presse, Francoise G., San Diego, CA, United States  
Vale, Jr., Wylie W., La Jolla, CA, United States  
PA The Salk Institute For Biological Studies, San Diego, CA, United States  
(U.S. corporation)  
PI US 5449766 19950912  
AI US 1994-208531 19940309 (8)

RLI Division of Ser. No. US 1991-733660, filed on 22 Jul 1991, now abandoned  
which is a division of Ser. No. US 1989-326984, filed on 22 Mar 1989, now patented, Pat. No. US 5049655

DT Utility  
LN.CNT 1307  
INCL INCLM: 536/023.500  
INCLS: 435/069.100; 435/069.400; 435/240.200; 435/252.300;  
435/320.100;  
530/300.000; 530/326.000; 536/022.100; 536/023.100  
NCL NCLM: 536/023.500  
NCLS: 435/069.100; 435/069.400; 435/252.300; 435/320.100;  
530/300.000;  
530/326.000; 536/022.100; 536/023.100

IC [6]  
ICM: C07H012-00  
ICS: C07H021-00; C12P021-06; C07K001-00  
EXF 435/69.1; 435/69.4; 435/240.2; 435/252.3; 435/320.1; 530/300;  
530/326;  
536/22.1; 536/23.1; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 31 OF 37 USPATFULL  
AN 95:73632 USPATFULL  
TI Lipoxin compounds  
IN Serhan, Charles N., Boston, MA, United States  
PA Brigham & Women's Hospital, Boston, MA, United States (U.S. corporation)  
PI US 5441951 19950815  
AI US 1994-260030 19940615 (8)  
DT Utility  
LN.CNT 2141  
INCL INCLM: 514/213.000  
INCLS: 514/552.000; 554/219.000; 554/224.000  
NCL NCLM: 514/513.000  
NCLS: 514/517.000; 514/552.000; 554/219.000; 554/224.000  
IC [6]  
ICM: C09F007-00  
ICS: A01N037-00; A61K031-00  
EXF 514/213; 514/552; 554/219; 554/224; 435/28; 424/534  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 32 OF 37 USPATFULL  
AN 95:20736 USPATFULL  
TI Imidazole 5-position substituted angiotensin II \*\*\*antagonists\*\*\*  
IN Duncia, John J. V., Wilmington, DE, United States  
Ensinger, Carol L., Newark, DE, United States  
Olson, Richard E., Wilmington, DE, United States  
Quan, Mimi L., Newark, DE, United States  
Santella, III, Joseph B., Springfield, PA, United States  
Vanatten, Mary K., Wilmington, DE, United States  
PA The Du Pont Merck Pharmaceutical Company, Wilmington, DE, United States  
(U.S. corporation)  
PI US 5395844 19950307  
AI US 1993-72977 19930610 (8)  
DT Utility  
LN.CNT 5135  
INCL INCLM: 514/333.000  
INCLS: 546/207.000; 546/210.000; 546/256.000; 546/276.000;  
548/253.000;  
548/314.700; 548/315.100; 548/335.100; 548/341.500; 548/343.500;  
548/346.100; 514/326.000; 514/341.000; 514/381.000; 514/396.000;  
514/397.000; 514/399.000; 514/400.000  
NCL NCLM: 514/333.000  
NCLS: 514/326.000; 514/341.000; 514/381.000; 514/396.000;  
514/397.000;  
514/399.000; 514/400.000; 544/139.000; 544/333.000; 544/405.000;  
546/022.000; 546/023.000; 546/146.000; 546/147.000; 546/174.000;  
546/207.000; 546/210.000; 546/256.000; 546/272.400; 546/274.400;  
546/274.700; 546/275.100; 548/253.000; 548/314.700; 548/315.100;

548/335.100; 548/341.500; 548/343.500; 548/346.100  
IC [6]  
ICM: A61K031-415  
ICS: C07D401-14; C07D403-02  
EXF 548/387; 548/253; 548/319.7; 548/315.1; 548/341.5; 548/335.1;  
548/343.5;  
548/346.1; 514/396; 514/398; 514/326; 514/341; 514/333; 514/381;  
514/397; 514/399; 514/400; 546/207; 546/210; 546/256; 546/276  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L8 ANSWER 33 OF 37 USPATFULL  
AN 93:59284 USPATFULL  
TI Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase  
IN Musser, John H., Alameda, CA, United States  
Kreft, III, Anthony F., Langhorne, PA, United States  
Failli, Amedeo A., Princeton Junction, NJ, United States  
Dernerson, Christopher A., Kirkland, Canada  
Shah, Uresh S., Plainsboro, NJ, United States  
Nelson, James A., Washington Crossing, PA, United States  
PA American Home Products Corporation, New York, NY, United States (U.S. corporation)  
PI US 5229516 19930720  
AI US 1992-911434 19920710 (7)  
RLI Continuation-in-part of Ser. No. US 1990-596134, filed on 11 Oct 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-428260, filed on 27 Oct 1989, now abandoned  
DT Utility  
LN.CNT 2630  
INCL INCLM: 546/172.000  
INCLS: 546/152.000; 546/174.000; 546/175.000; 546/176.000;  
546/180.000  
NCL NCLM: 546/172.000  
NCLS: 546/152.000; 546/174.000; 546/175.000; 546/176.000;  
546/180.000  
IC [5]  
ICM: C07D215-14  
ICS: C07D401-12; C07D405-14  
EXF 546/172; 546/152; 546/174; 546/175; 546/176; 546/180  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 34 OF 37 USPATFULL  
AN 92:59868 USPATFULL  
TI 11.beta.-phenyl-4,9,15-estratrienes, their manufacture and pharmaceutical preparations containing same  
IN Ottow, Eckhard, Berlin, Germany, Federal Republic of Hofmeister, Helmut, Berlin, Germany, Federal Republic of Scholz, Stefan, Berlin, Germany, Federal Republic of Neef, Guenter, Berlin, Germany, Federal Republic of Elger, Walter, Berlin, Germany, Federal Republic of Beier, Sybille, Berlin, Germany, Federal Republic of Chwalisz, Krzysztof, Berlin, Germany, Federal Republic of PA Schering Aktiengesellschaft, Berlin & Bergkamen, Germany, Federal Republic of (non-U.S. corporation)  
PI US 5132299 19920721  
WO 8900578 19890126  
AI US 1990-458668 19900116 (7)  
WO 1988-DE447 19880715  
19900116 PCT 371 date  
19900116 PCT 102(e) date  
PRAI DE 1987-3723788 19870716  
DT Utility  
LN.CNT 537  
INCL INCLM: 514/169.000  
INCLS: 514/179.000; 552/519.000; 552/623.000; 552/646.000  
NCL NCLM: 514/169.000  
NCLS: 514/179.000; 552/519.000; 552/623.000; 552/646.000  
IC [5]  
ICM: C07J001-00  
ICS: C07J041-00; A61K031-565

EXF 514/169; 514/179; 552/540; 552/544; 552/548; 552/553; 552/555;  
552/595;  
552/610; 552/611; 552/623; 552/519; 552/646

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 35 OF 37 USPATFULL

AN 91:75802 USPATFULL

TI Melanin-concentrating hormones

IN Vaughan, Joan, San Diego, CA, United States

Fischer, Wolfgang H., Solano Beach, CA, United States

Rivier, Jean E. F., La Jolla, CA, United States

Nahon, Jean-Louis M., San Diego, CA, United States

Presse, Francoise G., San Diego, CA, United States

Vale, Jr., Wylie W., La Jolla, CA, United States

PA The Salk Institute for Biological Studies, San Diego, CA, United States  
(U.S. corporation)

PI US 5049655 19910917

AI US 1989-326984 19890322 (7)

DT Utility

LN.CNT 1255

INCL INCLM: 530/326.000

INCLS: 536/027.000; 530/827.000; 530/854.000; 435/069.400;

435/320.100

NCL NCLM: 530/326.000

NCLS: 435/069.400; 435/320.100; 530/827.000; 530/854.000;

536/023.510

IC [5]

ICM: C07K007-64

ICS: C12N015-16

EXF 530/326; 530/827; 530/854; 536/27; 435/69.4; 435/320.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 36 OF 37 USPATFULL

AN 90:71762 USPATFULL

TI 2-dithioalkyl-dihydropyridines and pharmaceutical compositions containing them

IN Frigerio, Marco, Milan, Italy

Gandolfi, Carmelo A., Milan, Italy

Tognella, Sergio, Milan, Italy

PA Boehringer Biochimia Robin S.p.A., Milan, Italy (non-U.S. corporation)

PI US 4956369 19900911

AI US 1989-333815 19890406 (7)

RLI Continuation of Ser. No. US 1987-136988, filed on 23 Dec 1987, now abandoned

PRAI IT 1986-22881 19861224

DT Utility

LN.CNT 513

INCL INCLM: 514/274.000

INCLS: 546/321.000; 546/318.000; 546/316.000; 546/157.000;

546/281.000;

546/194.000; 546/256.000; 546/257.000; 546/283.000; 546/284.000;

546/276.000; 546/277.000; 546/278.000; 546/268.000; 546/270.000;

546/271.000; 546/286.000; 546/322.000; 544/360.000; 544/131.000;

544/333.000; 544/324.000; 544/262.000; 544/287.000; 544/318.000

NCL NCLM: 514/274.000

NCLS: 514/248.000; 514/252.160; 514/252.170; 514/252.180;

514/253.010;

514/253.130; 514/256.000; 514/265.000; 514/269.000; 514/275.000;

514/312.000; 514/333.000; 514/334.000; 514/336.000; 514/338.000;

514/339.000; 514/340.000; 514/341.000; 514/342.000; 514/343.000;

514/352.000; 514/356.000; 544/131.000; 544/262.000; 544/287.000;

544/318.000; 544/324.000; 544/333.000; 544/360.000; 546/157.000;

546/194.000; 546/256.000; 546/257.000; 546/268.400; 546/268.700;

546/270.100; 546/270.400; 546/271.400; 546/271.700; 546/272.400;

546/273.400; 546/274.100; 546/280.400; 546/281.400; 546/282.100;

546/283.400; 546/286.000; 546/316.000; 546/318.000; 546/321.000;

546/322.000

IC [5]

ICM: C07D401-12

ICS: A61K031-505

EXF 546/256; 546/257; 546/316; 546/318; 546/286; 546/322; 546/321;

546/270;  
546/218; 546/286; 546/157; 546/281; 546/194; 546/283; 546/284;

546/276;  
546/277; 546/268; 546/271; 544/318; 544/360; 544/131; 544/333;

544/324;  
544/262; 544/287; 514/269; 514/333; 514/334; 514/336; 514/341;

514/344;  
514/352; 514/355; 514/356; 514/343; 514/252; 514/255; 514/233;

514/342;  
514/256; 514/340; 514/342; 514/275; 514/248; 514/338; 514/339;

514/265;  
514/312

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 37 OF 37 USPATFULL

AN 83:11260 USPATFULL

TI Antiarrhythmic activity of cetiedil

IN Rousseau, Michel E. M., Paris, France

PA Innothera, Arcueil, France (non-U.S. corporation)

PI US 4377592 19830322

AI US 1979-88198 19791023 (6)

DT Utility

LN.CNT 542

INCL INCLM: 424/275.000

NCL NCLM: 514/217.030

NCLS: 514/821.000

IC [3]

ICM: A61K031-38

EXF 424/275

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 28 kwic

L8 ANSWER 28 OF 37 USPATFULL

AB Mammalian melanin-concentrating hormone ( \*\*\*MCH\*\*\* ) is isolated from

rat tissue, purified and characterized. These \*\*\*MCH\*\*\* peptides are useful for treating skin disorders, for suppressing the proliferation of skin tumor cells, such as melanomas in mammals, . . . #STR1## or which are naturally occurring homologs of the peptide with said formula. The peptides which are the naturally occurring \*\*\*MCH\*\*\* homologs of mammalian species other than rat can also be obtained using the materials disclosed, as demonstrated specifically with human \*\*\*MCH\*\*\* , which is found to have the same structure as rat \*\*\*MCH\*\*\* . Also disclosed are the amino acid sequences of, and the nucleotide sequences of the cDNAs which encode, the putative precursors of rat \*\*\*MCH\*\*\* and human \*\*\*MCH\*\*\* . These precursors may also include one or more biologically active peptides N-terminally of the mature \*\*\*MCH\*\*\* 's. Among these peptides, which are thought to be formed from the \*\*\*MCH\*\*\* precursors, are the peptide with the sequence H-Glu-Ile-Gly-Asp-Glu-Glu-Ser-Ala-Lys-Phe-Pro-Ile-NH.sub.2, which is

cross-reactive with antibodies against alpha-MSH and CRF, and the peptide. . .

SUMM . . . from salmon pituitary glands, see Kawauchi, H. et al., Nature, 305, 321-323 (1983), and it was named melanin concentrating hormone ( \*\*\*MCH\*\*\* ). Fish \*\*\*MCH\*\*\* has been reported to have the opposite effect, i.e., causing dispersal of melanosomes, in amphibians, Wilkes, B. C. et al., B.B.R.C., 122, 613-619 (1984). \*\*\*MCH\*\*\* is believed to be synthesized in the neurons of the hypothalamus and translocated into the neurohypophysial tissues. \*\*\*MCH\*\*\* immunoactivity has been reported in hypothalamic extracts of the rat: Baker et al., Gen. Comp. Endocrinol., 50, 423-431 (1983) and Naito, N. et al., Cell Tissue Res., 253, 291-295 (1988). Very crude extracts of an \*\*\*MCH\*\*\* -like substance from the rat hypothalamus showed a generally parallel response to fish \*\*\*MCH\*\*\* in a radioimmunoassay (RIA) using an antiserum directed against salmon \*\*\*MCH\*\*\* , even though the material appeared to have distinct chromatographic properties and showed multiple immunoreactive peaks, not all of which showed. . .

SUMM . . . years, the mammalian hormone remains unisolated and uncharacterized, and as a result, true testing of the biological activity of mammalian \*\*\*MCH\*\*\* has not heretofore been possible. As a result, great efforts were made to isolate, purify and then characterize and test mammalian \*\*\*MCH\*\*\*.

SUMM A mammalian \*\*\*MCH\*\*\* has now been isolated and purified from rat hypothalamus. Characterization of the purified peptide shows that it is 19 amino. . .

SUMM . . . of DNA probes based upon the characterized sequence of the peptide, it was possible to locate cDNAs coding for mammalian \*\*\*MCH\*\*\* from libraries made using rat and human hypothalamic messenger RNA. By isolating the cDNAs from the positive clones (i.e., those. . . the isolation and sequencing of the mature rat peptide, it was possible to determine that the C-terminus of the native \*\*\*MCH\*\*\* peptide is in the free acid form.

SUMM The amino acid sequences of the mature \*\*\*MCH\*\*\* 's of rat and human, as determined by the sequencing of the mature rat peptide and deduced from the sequences of. . . only three positions. The identity of amino acid sequences and close homology in cDNA sequences indicate that all mammalian mature \*\*\*MCH\*\*\* 's have sequences that are closely similar.

SUMM Further, from the sequencing of the cDNAs encoding the \*\*\*MCH\*\*\* precursors, it has been found that there is very close homology between the cDNA sequences and the corresponding amino acid. . .

SUMM Inasmuch as it appears that there is very close homology between the mature MCHs, \*\*\*MCH\*\*\* precursors, and mRNAs encoding these proteins

of mammalian species, it is believed that the DNA probes which are based upon the actual rat mature \*\*\*MCH\*\*\* peptide sequence (or other sequences provided herein using probes based on that rat peptide sequence) will be effective in identifying clones with \*\*\*MCH\*\*\*-encoding or \*\*\*MCH\*\*\* precursor-encoding cDNAs in libraries made with mRNAs obtained from appropriate tissue (e.g., hypothalamus) or cell lines of other mammalian species and thus will permit the determination of the sequences, and consequently the synthesis and use, of the mature \*\*\*MCH\*\*\* of every mammalian species.

SUMM Among the mammalian \*\*\*MCH\*\*\* 's, the present invention is especially concerned with the mature \*\*\*MCH\*\*\* having the following structure: #STR2##

SUMM Reference in the present application to a "mammalian \*\*\*MCH\*\*\*" is to a mammalian mature \*\*\*MCH\*\*\*, unless the term is explicitly qualified to refer to a mammalian \*\*\*MCH\*\*\* precursor.

SUMM Mammalian \*\*\*MCH\*\*\* is useful to treat humans and other mammals to lighten skin color, as by local or topical application. It is. . . cells, such as melanomas, when suitably applied as by topical application or the like. It is also found that mammalian \*\*\*MCH\*\*\* can be used to modulate the secretion of ACTH in humans and other mammals and thus can be used to modify the effects of stress, as by systemically administering an effective amount of mammalian \*\*\*MCH\*\*\*.

SUMM . . . as its sequence  
Glu-Ile-Gly-Asp-Glu-Glu-Asn-Ser-Ala-Lys-Phe-Pro-Ile-NH<sub>sub</sub>.2. A mammalian NEI is apparently made in vivo in a mammal by processing beginning with the \*\*\*MCH\*\*\* precursor of the mammal. The sequences of all mammalian NEI's are closely similar, as indicated by the fact that the. . .

SUMM . . . NGE). Like NEI, a mammalian NGE is apparently also made in vivo in a mammal by processing beginning with the \*\*\*MCH\*\*\* precursor of the mammal. Further, the sequences of all mammalian NGE's are closely similar, as indicated by the fact that. . .

SUMM The sequence of NEI corresponds to the sequence of amino acids 131-144

of the rat and human \*\*\*MCH\*\*\* precursors (see Tables 1 and 2, below), taking account of the fact that the glycine at position 144 of the \*\*\*MCH\*\*\* precursors would provide the NH<sub>sub</sub>.2 group of the C-terminal amide of NEI. It has been found that antibodies against human. . .

SUMM The sequences of the NGE's correspond to the sequences of amino acids 110-128 of the \*\*\*MCH\*\*\* precursors (see Tables 1 and 2, below). Antibodies against human GRF (growth hormone releasing factor) cross-react with NGE, as suggested. . .

SUMM Mammalian melanin-concentrating hormone ( \*\*\*MCH\*\*\* ) has now been isolated from rat hypothalamus by acid extraction and purified substantially by immunoaffinity chromatography using antiserum directed against salmon \*\*\*MCH\*\*\*, gel filtration and two steps of narrow bore high-performance liquid chromatography (HPLC) using octadecyl columns. Several zones of immunoreactivity were. . . indicates that the amino acid structure of all zones are identical. As a result, it is believed that rat hypothalamic \*\*\*MCH\*\*\* is a cyclic peptide of 19 amino acid residues. More particularly, the invention provides peptides having the following structure: #STR3## and naturally occurring homologs thereof (i.e., homologous \*\*\*MCH\*\*\* peptides of mammalian species other than rat and human (for which the structure of the \*\*\*MCH\*\*\* is identical to that of rat)).

SUMM . . . a synthetic oligonucleotide probe with a sequence which was based on the sequence of residues 1-10 of the above-identified, mature \*\*\*MCH\*\*\* sequence of rat. Several positive hits were obtained, and the culturing of the positive clones allowed the isolation of cDNAs encoding the entire precursor of rat \*\*\*MCH\*\*\*. With such cDNA, the nucleotide sequence coding the precursor was determined and, with the nucleotide sequence, the amino acid sequence of the precursor deduced. This work confirmed that the mature \*\*\*MCH\*\*\* peptide has the above-identified structure and is free acid at the C-terminus. Further, the work provided the information from which. . .

SUMM Substantially the same procedure was followed to isolate and sequence cDNAs encoding the human \*\*\*MCH\*\*\* precursor. To isolate such cDNAs,

a human hypothalamic cDNA library was screened with a probe taken from a

portion, encoding part of rat mature \*\*\*MCH\*\*\*, of the cDNA encoding the rat \*\*\*MCH\*\*\* precursor. Using the sequence information from the cDNAs encoding the human \*\*\*MCH\*\*\* precursor, the amino acid sequences of human mature \*\*\*MCH\*\*\*, its precursor, and human NEI and NGE were deduced.

SUMM A portion, encoding mature \*\*\*MCH\*\*\* with the dipeptide Arg-Arg, which is a proteolytic processing site, at the N-terminus, of the oligonucleotide sequence of the rat. . .

SUMM Human mature \*\*\*MCH\*\*\* has the same amino acid sequence as that of

rat and, like the rat, is preceded by the dipeptide Arg-Arg in the human \*\*\*MCH\*\*\* precursor. As indicated in Tables 1 and 2 below, the nucleotide sequence of the cDNA segment encoding human mature \*\*\*MCH\*\*\* and the Arg-Arg preceding the protein in the precursor differs at only three of 57 positions from the sequence of. . .

SUMM . . . and based on the high degree of homology found in connection with the present invention between rat and human mature \*\*\*MCH\*\*\* 's and \*\*\*MCH\*\*\* precursors, and the cDNAs encoding same, possession of the above-identified rat and human nucleotide sequences allows the construction of nucleic acid probes that will hybridize with cDNA fragments, coding for the mature \*\*\*MCH\*\*\* and \*\*\*MCH\*\*\* precursor, in a cDNA library of suitable tissue (e.g., the hypothalamus), or a suitable cell line, of any mammalian species, . . . libraries as described above. Thus, possession of the sequences allows deduction of the specific amino acid sequences of the mature \*\*\*MCH\*\*\* hormone and NEI and NGE of such other species. Such techniques of using a suitable hybridization probe for screening and. . .

SUMM . . . the complementary strand of the above-specified strand of the rat cDNA sequence, was employed for probing for cDNAs encoding human \*\*\*MCH\*\*\* and its precursor and as expected, hybridized with clones of a human lambda.gt11 cDNA library prepared with human hypothalamic mRNA.

SUMM Isolation of a cDNA coding for mammalian \*\*\*MCH\*\*\* or

\*\*\*MCH\*\*\*

precursor of another particular species, as has been accomplished for the rat and human species, will allow, as it has for the rat and human, the determination of the amino acid sequence of the \*\*\*MCH\*\*\* peptide, as well as of the NEI and NGE, of the species.

SUMM . . . acids in the peptides, using solid-phase or other types of chemical syntheses. Thus, the invention provides methods for producing  
-----User Break-----

u

=>

=> d 35 kwic

L8 ANSWER 35 OF 37 USPATFULL

AB Mammalian melanin-concentrating hormone ( \*\*\*MCH\*\*\* ) is isolated from

rat tissue, purified and characterized. These \*\*\*MCH\*\*\* peptides are useful for treating skin disorders, for suppressing the proliferation of skin tumor cells, such as melanomas in mammals, . . . ##STR1## or which are naturally occurring homologs of the peptide with said formula. The peptides which are the naturally occurring \*\*\*MCH\*\*\* homologs of mammalian species other than rat can also be obtained using the materials disclosed, as demonstrated specifically with human \*\*\*MCH\*\*\*, which is found to have the same structure as rat \*\*\*MCH\*\*\*. Also disclosed are the amino acid sequences of, and the nucleotide sequences of the cDNAs which encode, the putative precursors of rat \*\*\*MCH\*\*\* and human \*\*\*MCH\*\*\*. These precursors may also include one or more biologically active peptides N-terminally of the mature \*\*\*MCH\*\*\*'s. Among these peptides, which are thought to be formed from the \*\*\*MCH\*\*\* precursors, are the peptide with the sequence H-Glu-Ile-Gly-Asp-Glu-Glu-Ser-Ala-Lys-Phe-Pro-Ile-NH.sub.2, which is cross-reactive with antibodies against alpha-MSH and CRF, and the peptide. . .

SUMM . . . from salmon pituitary glands, see Kawauchi, H. et al., Nature, 305, 321-323 (1983), and it was named melanin concentrating hormone ( \*\*\*MCH\*\*\* ). Fish \*\*\*MCH\*\*\* has been reported to have the opposite effect, i.e., causing dispersal of melanosomes, in amphibians, Wilkes, B. C. et al., B.B.R.C., 122, 613-619 (1984). \*\*\*MCH\*\*\* is believed to be synthesized in the neurons of the hypothalamus and translocated into the neurohypophyseal tissues. \*\*\*MCH\*\*\* immunoactivity has been reported in hypothalamic extracts of the rat: Baker et al., Gen. Comp. Endocrinol., 50, 423-431 (1983) and Naito, N. et al., Cell Tissue Res., 253, 291-295 (1988). Very crude extracts of an \*\*\*MCH\*\*\* -like substance from the rat hypothalamus showed a generally parallel response to fish \*\*\*MCH\*\*\* in a radioimmunoassay (RIA) using an antiserum directed against salmon \*\*\*MCH\*\*\*, even though the material appeared to have distinct chromatographic properties and showed multiple immunoreactive peaks, not all of which showed. . .

SUMM . . . years, the mammalian hormone remains unisolated and uncharacterized, and as a result, true testing of the biological activity of mammalian \*\*\*MCH\*\*\* has not heretofore been possible. As a result, great efforts were made to isolate, purify and then characterize and test mammalian \*\*\*MCH\*\*\*.

SUMM A mammalian \*\*\*MCH\*\*\* has now been isolated and purified from rat

hypothalamus. Characterization of the purified peptide shows that it is 19 amino. . .

SUMM . . . of DNA probes based upon the characterized sequence of the peptide, it was possible to locate cDNAs coding for mammalian \*\*\*MCH\*\*\* from libraries made using rat and human hypothalamic messenger RNA. By isolating the cDNAs from the positive clones (i.e., those. . . the isolation and sequencing of the mature rat peptide, it was possible to determine that the C-terminus of the native \*\*\*MCH\*\*\* peptide is in the free acid form.

SUMM The amino acid sequences of the mature \*\*\*MCH\*\*\*'s of rat and human, as determined by the sequencing of the mature rat peptide and deduced from the sequences of. . . only three positions. The identity of amino acid sequences and close homology in cDNA sequences indicate that all mammalian mature \*\*\*MCH\*\*\*'s have sequences that are closely

similar.

SUMM Further, from the sequencing of the cDNAs encoding the \*\*\*MCH\*\*\*

precursors, it has been found that there is very close homology between the cDNA sequences and the corresponding amino acid. . .

SUMM Inasmuch as it appears that there is very close homology between the mature MCHs, \*\*\*MCH\*\*\* precursors, and mRNAs encoding these proteins

of mammalian species, it is believed that the DNA probes which are based upon the actual rat mature \*\*\*MCH\*\*\* peptide sequence (or other sequences provided herein using probes based on that rat peptide sequence) will be effective in identifying clones with \*\*\*MCH\*\*\*-encoding or \*\*\*MCH\*\*\* precursor-encoding cDNAs in libraries made with mRNAs obtained from appropriate tissue (e.g., hypothalamus) or cell lines of other mammalian species and thus will permit the determination of the sequences, and consequently the synthesis and use, of the mature \*\*\*MCH\*\*\* of every mammalian species.

SUMM Among the mammalian \*\*\*MCH\*\*\*'s, the present invention is especially

concerned with the mature \*\*\*MCH\*\*\* having the following structure: ##STR2##

SUMM Reference in the present application to a "mammalian \*\*\*MCH\*\*\*" is to a mammalian mature \*\*\*MCH\*\*\*, unless the term is explicitly qualified to refer to a mammalian \*\*\*MCH\*\*\* precursor.

SUMM Mammalian \*\*\*MCH\*\*\* is useful to treat humans and other mammals to

lighten skin color, as by local or topical application. It is. . . cells, such as melanomas, when suitably applied as by topical application or the like. It is also found that mammalian \*\*\*MCH\*\*\* can be used to modulate the secretion of ACTH in humans and other mammals and thus can be used to modify the effects of stress, as by systemically administering an effective amount of mammalian \*\*\*MCH\*\*\*

SUMM . . . as its sequence

Glu-Ile-Gly-Asp-Glu-Glu-Ser-Ala-Lys-Phe-Pro-Ile-NH.sub.2. A mammalian NEI is apparently made in vivo in a mammal by

processing beginning with the \*\*\*MCH\*\*\* precursor of the mammal. The sequences of all mammalian NEI's are closely similar, as indicated by the fact that the. . .

SUMM . . . NGE. Like NEI, a mammalian NGE is apparently also made in vivo

in a mammal by processing beginning with the \*\*\*MCH\*\*\* precursor of the mammal. Further, the sequences of all mammalian NGE's are closely similar, as indicated by the fact that. . .

SUMM The sequence of NEI corresponds to the sequence of amino acids 131-144

of the rat and human \*\*\*MCH\*\*\* precursors (see Tables 1 and 2, below), taking account of the fact that the glycine at position 144 of the \*\*\*MCH\*\*\* precursors would provide the NH.sub.2 group of the C-terminal amide of NEI. It has been found that antibodies against human. . .

SUMM The sequences of the NGE's correspond to the sequences of amino acids 110-128 of the \*\*\*MCH\*\*\* precursors (see Tables 1 and 2, below).

Antibodies against human GRF (growth hormone releasing factor) cross-react with NGE, as suggested. . .

DETQ Mammalian melanin-concentrating hormone ( \*\*\*MCH\*\*\* ) has now been

isolated from rat hypothalamus by acid extraction and purified substantially by immunoaffinity chromatography using antiserum directed against salmon \*\*\*MCH\*\*\*, gel filtration and two steps of narrow bore high-performance liquid chromatography (HPLC) using octadecyl columns. Several zones of immunoreactivity were. . . indicates that the amino acid structure of all zones are identical. As a result, it is believed that rat hypothalamic \*\*\*MCH\*\*\* is a cyclic peptide of 19 amino acid residues. More particularly, the invention provides peptides having the following structure: ##STR3## and naturally occurring homologs thereof (i.e., homologous \*\*\*MCH\*\*\* peptides of mammalian species other than rat and human (for which the structure of the

\*\*\*MCH\*\*\* is identical to that of rat)).

DET<sup>D</sup>T . . . a synthetic oligonucleotide probe with a sequence which was based on the sequence of residues 1-10 of the above-identified, mature \*\*\*MCH\*\*\* sequence of rat. Several positive hits were obtained, and the culturing of the positive clones allowed the isolation of cDNAs encoding the entire precursor of rat \*\*\*MCH\*\*\*. With such cDNA, the nucleotide sequence coding the precursor was determined and, with the nucleotide sequence, the amino acid sequence of the precursor deduced. This work confirmed that the mature \*\*\*MCH\*\*\* peptide has the above-identified structure and is free acid at the C-terminus. Further, the work provided the information from which. . . .  
DET<sup>D</sup>T Substantially the same procedure was followed to isolate and sequence cDNAs encoding the human \*\*\*MCH\*\*\* precursor. To isolate such cDNAs, a human hypothalamic cDNA library was screened with a probe taken from a portion, encoding part of rat mature \*\*\*MCH\*\*\*, of the cDNA encoding the rat \*\*\*MCH\*\*\* precursor. Using the sequence information from the cDNAs encoding the human \*\*\*MCH\*\*\* precursor, the amino acid sequences of human mature \*\*\*MCH\*\*\*, its precursor, and human NEI and NGE were deduced.

DET<sup>D</sup>T A portion, encoding mature \*\*\*MCH\*\*\* with the dipeptide Arg-Arg, which is a proteolytic processing site, at the N-terminus, of the oligonucleotide sequence of the rat. . . .

DET<sup>D</sup>T Human mature \*\*\*MCH\*\*\* has the same amino acid sequence as that of

rat and, like the rat, is preceded by the dipeptide Arg-Arg in the human \*\*\*MCH\*\*\* precursor. As indicated in Tables 1 and 2 below, the nucleotide sequence of the cDNA segment encoding human mature \*\*\*MCH\*\*\* and the Arg-Arg preceding the protein in the precursor

<-----User Break----->

u

=>

=> log y

COST IN U.S. DOLLARS	ENTRY	SINCE FILE	TOTAL
FULL ESTIMATED COST		SESSION	
		78.59	78.74

STN INTERNATIONAL LOGOFF AT 12:25:19 ON 13 SEP 2000

FILE 'HOME' ENTERED AT 12:26:30 ON 13 SEP 2000

=> file medline, embase, biosis

COST IN U.S. DOLLARS	ENTRY	SINCE FILE	TOTAL
FULL ESTIMATED COST		SESSION	
		0.15	0.15

FILE 'MEDLINE' ENTERED AT 12:26:41 ON 13 SEP 2000

FILE 'EMBASE' ENTERED AT 12:26:41 ON 13 SEP 2000  
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 12:26:41 ON 13 SEP 2000  
COPYRIGHT (C) 2000 BIOSIS(R)

=> s melanocyte concentrating hormone or mch

L1 4209 MELANOCYTE CONCENTRATING HORMONE OR MCH

=> s II and antagoni?

L2 234 L1 AND ANTAGONI?

=> s I2 and (eat? or appetite or weight)

L3 16 L2 AND (EAT? OR APPETITE OR WEIGHT)

=> duplicate remove l3

DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS'  
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L3

L4 9 DUPLICATE REMOVE L3 (7 DUPLICATES REMOVED)

=> d 1-9

L4 ANSWER 1 OF 9 MEDLINE  
AN 2000119108 MEDLINE  
DN 20119108

DUPLICATE 1

TI Differential regulation of melanin-concentrating hormone and orexin genes in the agouti-related protein/melanocortin-4 receptor system.

AU Hanada R; Nakazato M; Matsukura S; Murakami N; Yoshimatsu H; Sakata T

CS Department of Internal Medicine I, School of Medicine, Oita Medical University, Oita, 879-5593, Japan.

SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2000 Feb 5) 268 (1)

88-91.

Journal code: 9Y8. ISSN: 0006-291X.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 200005

EW 20000501

L4 ANSWER 2 OF 9 MEDLINE  
AN 1999347735 MEDLINE  
DN 99347735

DUPLICATE 2

TI Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1.

AU Chambers J; Ames R S; Bergsma D; Muir A; Fitzgerald L R; Hervieu G; Dytko

G M; Foley J J; Martin J; Liu W S; Park J; Ellis C; Ganguly S; Konchar S; Cluderay J; Leslie R; Wilson S; Sarau H M

CS Department of Molecular Screening Technologies, New Frontiers Science Park, SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK..  
Jon\_Chambers-1@sbphrd.com

- SO NATURE, (1999 Jul 15) 400 (6741) 261-5.  
 Journal code: NSC. ISSN: 0028-0836.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals; Cancer Journals  
 EM 199910
- L4 ANSWER 3 OF 9 MEDLINE  
 AN 1999008618 MEDLINE  
 DN 99008618  
 TI Leptin decreases food intake induced by melanin-concentrating hormone (\*\*\*MCH\*\*\*), galanin (GAL) and neuropeptide Y (NPY) in the rat.  
 AU Sahu A  
 CS Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, PA 15261, USA.. asahu@vms.cis.pitt.edu  
 SO ENDOCRINOLOGY, (1998 Nov) 139 (11) 4739-42.  
 Journal code: EGZ. ISSN: 0013-7227.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals  
 EM 199901
- L4 ANSWER 4 OF 9 MEDLINE DUPLICATE 3  
 AN 1998236737 MEDLINE  
 DN 98236737  
 TI Melanin-concentrating hormone: a functional melanocortin \*\*\*antagonist\*\*\* in the hypothalamus.  
 AU Ludwig D S; Mountjoy K G; Tatro J B; Gillette J A; Frederich R C; Flier J S; Maratos-Flier E  
 CS Department of Medicine, Beth Israel-Deaconess Medical Center, Boston, Massachusetts, USA.  
 NC R08-DK-02440 (NIDDK)  
 MH-44694 (NIMH)  
 SO AMERICAN JOURNAL OF PHYSIOLOGY, (1998 Apr) 274 (4 Pt 1) E627-33.  
 Journal code: 3U8. ISSN: 0002-9513.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199808  
 EW 19980801
- L4 ANSWER 5 OF 9 MEDLINE  
 AN 96270476 MEDLINE  
 DN 96270476  
 TI Activation of beta(3) adrenergic receptors suppresses leptin expression and mediates a leptin-independent inhibition of food intake in mice.  
 AU Mantzoros C S; Qu D; Frederich R C; Susulic V S; Lowell B B; Maratos-Flier E; Flier J S  
 CS Division of Endocrinology, Beth Israel Hospital, Boston, Massachusetts, USA.  
 NC P30DK462000 (NIDDK)  
 K08 HL-02564 (NHLBI)  
 K08 DK-02119 (NIDDK)  
 SO DIABETES, (1996 Jul) 45 (7) 909-14.  
 Journal code: E8X. ISSN: 0012-1797.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 199610
- L4 ANSWER 6 OF 9 EMBASE COPYRIGHT 2000 ELSEVIER SCI.  
 B.V.DUPLICATE 4  
 AN 95322343 EMBASE  
 DN 1995322343
- TI Toxicological studies of lafutidine (FRG-8813) 5. Thirteen-week repeated dose toxicity study by oral administration to beagle dogs with a recovery period of 4 weeks.  
 AU Kobayashi K.; Hashiguchi J.-I.; Okamura T.; Enomoto M.; Hayashi Y.  
 CS BRCFDP, 582-2 Arahamo, Shiosinden,Iwata-gun, Shizuoka 437 12, Japan  
 SO Pharmacometrics, (1995) 50/4 (421-438).  
 ISSN: 0300-8533 CODEN: OYYAA2  
 CY Japan  
 DT Journal; Article  
 FS 030 Pharmacology  
 037 Drug Literature Index  
 052 Toxicology  
 LA Japanese  
 SL English
- L4 ANSWER 7 OF 9 MEDLINE  
 AN 93182873 MEDLINE  
 DN 93182873  
 TI Distribution of secretory leukoprotease inhibitor in the human nasal airway.  
 AU Lee C H; Igarashi Y; Hohman R J; Kaulbach H; White M V; Kaliner M A  
 CS Allergic Diseases Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.  
 SO AMERICAN REVIEW OF RESPIRATORY DISEASE, (1993 Mar) 147 (3) 710-6.  
 Journal code: 426. ISSN: 0003-0805.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 199306
- L4 ANSWER 8 OF 9 MEDLINE DUPLICATE 4  
 AN 93265734 MEDLINE  
 DN 93265734  
 TI Inhibition of delta aminolevulinic acid dehydratase activity by aluminum.  
 AU Zaman K; Zaman W; Dabrowski Z; Misztal H  
 CS Department of Pathology, School of Medicine, University of Pennsylvania, Philadelphia.  
 SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. C: COMPARATIVE PHARMACOLOGY AND TOXICOLOGY, (1993 Feb) 104 (2) 269-73.  
 Journal code: DNX. ISSN: 0742-8413.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199308
- L4 ANSWER 9 OF 9 MEDLINE DUPLICATE 5  
 AN 93115167 MEDLINE  
 DN 93115167  
 TI M1 and M3 muscarinic \*\*\*antagonists\*\*\* inhibit human nasal glandular secretion in vitro.  
 AU Mullol J; Baraniuk J N; Logun C; Merida M; Hausfeld J; Shelhamer J H; Kaliner M A  
 CS Servei de Pneumologia i Allergia Respiratoria, Hospital Clinic, Barcelona, Spain..  
 SO JOURNAL OF APPLIED PHYSIOLOGY, (1992 Nov) 73 (5) 2069-73.  
 Journal code: HEG. ISSN: 8750-7587.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199304
- => d 1-4 abs

#### L4 ANSWER 1 OF 9 MEDLINE

DUPLICATE 1  
AB Agouti protein and agouti-related protein (AGRP) \*\*\*antagonize\*\*\* alpha-melanocyte-stimulating hormone that binds to and activates the melanocortin-4 receptor (MC4-R) in the hypothalamus, thereby stimulating food intake. Melanin-concentrating hormone ( \*\*\*MCH\*\*\* ) and orexin are orexigenic peptides that specifically are synthesized in the lateral hypothalamus. \*\*\*MCH\*\*\* gene expression was augmented in A(y/a) (agouti) mice which overexpress agouti protein, but orexin mRNA was not. AGRP administered intracerebroventricularly into wild-type rats augmented \*\*\*MCH\*\*\* but not orexin gene expression. Also, SHU9119, a peptidergic \*\*\*antagonist\*\*\* of MC4-R, increased only \*\*\*MCH\*\*\* mRNA. These findings indicate that interruption of signaling at MC4-R activates the \*\*\*MCH\*\*\* but not the orexin gene. The biosyntheses of \*\*\*MCH\*\*\* and

orexin are regulated through different pathways. Copyright 2000 Academic Press.

#### L4 ANSWER 2 OF 9 MEDLINE

DUPLICATE 2  
AB The underlying causes of obesity are poorly understood but probably involve complex interactions between many neurotransmitter and neuropeptide systems involved in the regulation of food intake and energy balance. Three pieces of evidence indicate that the neuropeptide melanin-concentrating hormone ( \*\*\*MCH\*\*\* ) is an important component of

this system. First, \*\*\*MCH\*\*\* stimulates feeding when injected directly into rat brains; second, the messenger RNA for the \*\*\*MCH\*\*\* precursor is upregulated in the hypothalamus of genetically obese mice and in fasted animals; and third, mice lacking \*\*\*MCH\*\*\* \*\*\*eat\*\*\* less and are lean. \*\*\*MCH\*\*\* \*\*\*antagonists\*\*\* might, therefore, provide a treatment for obesity. However, the development of such molecules has been hampered because the identity of the \*\*\*MCH\*\*\* receptor has been unknown until now. Here we show that the 353-amino-acid human orphan G-protein-coupled receptor SLC-1 expressed in HEK293 cells binds \*\*\*MCH\*\*\* with sub-nanomolar affinity, and is stimulated by \*\*\*MCH\*\*\* to mobilize intracellular Ca<sup>2+</sup> and reduce forskolin-elevated cyclic AMP levels. We also show that SLC-1 messenger RNA and protein is expressed in the ventromedial and dorsomedial nuclei of the hypothalamus, consistent with a role for SLC-1 in mediating the effects of \*\*\*MCH\*\*\* on feeding.

#### L4 ANSWER 3 OF 9 MEDLINE

AB Recent evidence suggests that leptin reduces food intake (FI) by acting at the hypothalamic level. Leptin decreases hypothalamic neuropeptide Y (NPY), melanin-concentrating hormone ( \*\*\*MCH\*\*\* ) and galanin (GAL) gene expression in rats. The purpose of the present study was to test the hypothesis that leptin decreases FI by additionally modulating the action of NPY, \*\*\*MCH\*\*\* or GAL in the hypothalamus. Intracerebroventricular (i.c.v.) administration of NPY, \*\*\*MCH\*\*\* or GAL induced FI in sated rats. A prior i.c.v. injection of leptin (4 microg) completely prevented the increase of FI either by \*\*\*MCH\*\*\* , GAL or NPY. These results suggest that modulation of post-synaptic actions of \*\*\*MCH\*\*\* , GAL and NPY is one of the mechanisms of leptin signaling in the hypothalamus.

#### L4 ANSWER 4 OF 9 MEDLINE

DUPLICATE 3  
AB Melanin-concentrating hormone ( \*\*\*MCH\*\*\* ) and alpha-melanocyte-stimulating hormone (alpha-MSH) demonstrate opposite actions on skin coloration in teleost fish. Both peptides are present in the mammalian brain, although their specific physiological roles remain largely unknown. In this study, we examined the interactions between \*\*\*MCH\*\*\* and alpha-MSH after intracerebroventricular administration in rats.

\*\*\*MCH\*\*\* increased food intake in a dose-dependent manner and lowered plasma glucocorticoid levels through a mechanism involving ACTH. In contrast, alpha-MSH decreased food intake and increased glucocorticoid levels. \*\*\*MCH\*\*\* , at a twofold molar excess, \*\*\*antagonized\*\*\* both actions of alpha-MSH. alpha-MSH, at a threefold molar excess, blocked the orexigenic properties of \*\*\*MCH\*\*\* . \*\*\*MCH\*\*\* did not block alpha-MSH binding or the ability of alpha-MSH to induce cAMP in cells expressing either the MC3 or MC4 receptor, the principal brain alpha-MSH receptor subtypes. These data suggest that \*\*\*MCH\*\*\* and alpha-MSH

exert opposing and \*\*\*antagonistic\*\*\* influences on feeding behavior and the stress response and may function in a coordinate manner to regulate metabolism through a novel mechanism mediated in part by an \*\*\*MCH\*\*\* receptor.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	8.42	8.57

STN INTERNATIONAL LOGOFF AT 12:31:46 ON 13 SEP 2000

FILE 'HOME' ENTERED AT 10:08:19 ON 14 SEP 2000

=> file medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 10:08:46 ON 14 SEP 2000

FILE LAST UPDATED: 7 SEP 2000 (20000907/UP). FILE COVERS 1960 TO DATE.

MEDLINE has been reloaded to reflect the annual MeSH changes made by the National Library of Medicine for 2000. Enter HELP RLOAD for details.

The OLDMEDLINE file segment now contains data from 1958 through 1965. Enter HELP CONTENT for details.

Left, right, and simultaneous left and right truncation are available in the Basic Index. See HELP SFIELDS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

=> s caffeine

L1 15528 CAFFEINE

=> s l1 and weight loss

445116 WEIGHT  
222176 LOSS  
18662 WEIGHT LOSS  
(WEIGHT(W)LOSS)  
L2 54 L1 AND WEIGHT LOSS

=> s l2 and review

L3 237562 REVIEW  
2 L2 AND REVIEW

=> d 1-2

L3 ANSWER 1 OF 2 MEDLINE  
AN 2000186121 MEDLINE  
DN 20186121  
TI The effectiveness of popular, non-prescription \*\*\*weight\*\*\*  
\*\*\*loss\*\*\* supplements [see comments].  
CM Comment in: Med J Aust 1999 Dec 6-20;171(11-12):599-600  
AU Egger G; Cameron-Smith D; Stanton R  
CS School of Health Sciences, Deakin University, Melbourne, Vic..  
eggergj@ozemail.com.au  
SO MEDICAL JOURNAL OF AUSTRALIA, (1999 Dec 6-20) 171 (11-12)  
604-8. Ref: 69  
Journal code: M26. ISSN: 0025-729X.

CY Australia  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals; Cancer Journals  
EM 200006  
EW 20000602

L3 ANSWER 2 OF 2 MEDLINE  
AN 97081303 MEDLINE  
DN 97081303  
TI Dexfenfluramine. An updated \*\*\*review\*\*\* of its therapeutic use in the

management of obesity.

AU Davis R; Faulds D  
CS Adis International Limited, Auckland, New Zealand.  
SO DRUGS, (1996 Nov) 52 (5) 696-724. Ref: 167  
Journal code: EC2. ISSN: 0012-6667.  
CY New Zealand  
DT (CLINICAL TRIAL)  
(CONTROLLED CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, ACADEMIC)  
LA English  
FS Priority Journals  
EM 199706

=> s water and weight and obesity

212635 WATER  
445116 WEIGHT  
51496 OBESITY  
L4 597 WATER AND WEIGHT AND OBESITY

=> s water and obesity and eat?

212635 WATER  
51496 OBESITY  
41129 EAT?  
L5 114 WATER AND OBESITY AND EAT?

=> d 100-114

L5 ANSWER 100 OF 114 MEDLINE  
AN 77220067 MEDLINE  
DN 77220067  
TI [Dietary behavior and cardiovascular diseases].  
Comportement alimentaire et maladies cardiovasculaires.

AU Debry G  
SO ANNALES DE LA NUTRITION ET DE L ALIMENTATION, (1976) 30  
(2-3) 219-33.  
Ref: 102  
Journal code: SNO. ISSN: 0003-4037.  
CY France  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LA French  
FS Priority Journals  
EM 197710

L5 ANSWER 101 OF 114 MEDLINE  
AN 77099409 MEDLINE  
DN 77099409  
TI The role of vasopressin and prolactin in abnormal salt and \*\*\*water\*\*\*  
metabolism of obese patients before and after fasting and during  
refeeding.  
AU Drenick E J; Carlson H E; Robertson G L; Hershman J M  
SO METABOLISM: CLINICAL AND EXPERIMENTAL, (1977 Mar) 26 (3)  
309-17.  
Journal code: MUM. ISSN: 0026-0495.

CY United States  
DT (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 197705

L5 ANSWER 102 OF 114 MEDLINE  
AN 77011151 MEDLINE  
DN 77011151  
TI Metabolic responses to dietary supplements of bran.

- AU Southgate D A; Branch W J; Hill M J; Drasar B S; Walters R L; Davies P S;  
 Baird I M  
 SO METABOLISM: CLINICAL AND EXPERIMENTAL, (1976 Oct) 25 (10) 1129-35.  
 Journal code: MUM. ISSN: 0026-0495.
- CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 197701
- L5 ANSWER 103 OF 114 MEDLINE  
 AN 74109640 MEDLINE  
 DN 74109640  
 TI Role of past experience on food-motivated behavior of obese humans.  
 AU Singh D; Sikes S  
 SO JOURNAL OF COMPARATIVE AND PHYSIOLOGICAL PSYCHOLOGY, (1974 Mar) 86 (3) 503-8.  
 Journal code: HVR. ISSN: 0021-9940.
- CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 197406
- L5 ANSWER 104 OF 114 MEDLINE  
 AN 74077040 MEDLINE  
 DN 74077040  
 TI Food motivation and body weight levels in hypothalamic hyperphage rats: a dual lipostat model of hunger and appetite.  
 AU Scalfani A; Kluge L  
 SO JOURNAL OF COMPARATIVE AND PHYSIOLOGICAL PSYCHOLOGY, (1974 Jan) 86 (1) 28-46.  
 Journal code: HVR. ISSN: 0021-9940.
- CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 197404
- L5 ANSWER 105 OF 114 MEDLINE  
 AN 74009073 MEDLINE  
 DN 74009073  
 TI Feeding and drinking pathways between medial and lateral hypothalamus in the rat.  
 AU Scalfani A; Berner C N; Maul G  
 SO JOURNAL OF COMPARATIVE AND PHYSIOLOGICAL PSYCHOLOGY, (1973 Oct) 85 (1) 29-51.  
 Journal code: HVR. ISSN: 0021-9940.
- CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 197401
- L5 ANSWER 106 OF 114 MEDLINE  
 AN 73234043 MEDLINE  
 DN 73234043  
 TI Basic drives.  
 AU Wayner M J; Carey R J  
 SO ANNUAL REVIEW OF PSYCHOLOGY, (1973) 24 53-80. Ref: 156  
 Journal code: 6EB. ISSN: 0066-4308.
- CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Priority Journals
- EM 197311
- L5 ANSWER 107 OF 114 MEDLINE  
 AN 72242491 MEDLINE  
 DN 72242491  
 TI Taste sensitivity and susceptibility to external influence in obese and normal weight subjects.  
 AU Grinker J; Hirsch J; Smith D V  
 SO JOURNAL OF PERSONALITY AND SOCIAL PSYCHOLOGY, (1972 Jun) 22 (3) 320-5.  
 Journal code: JN3. ISSN: 0022-3514.
- CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 197211
- L5 ANSWER 108 OF 114 MEDLINE  
 AN 71018840 MEDLINE  
 DN 71018840  
 TI [Importance of \*\*\*water\*\*\* quantity in infant nutrition, especially in the fight against \*\*\*obesity\*\*\* ].  
 L'importance de la ration hydrique dans l'alimentation du nourrisson, en particulier dans la lutte contre l'obésité.  
 AU Du Pan M  
 SO PEDIATRIE, (1968 Apr-May) 23 (3) 295-309.  
 Journal code: OY8. ISSN: 0031-4021.
- CY France  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA French  
 EM 197101
- L5 ANSWER 109 OF 114 MEDLINE  
 AN 70284941 MEDLINE  
 DN 70284941  
 TI Metabolic aspects of \*\*\*obesity\*\*\* .  
 AU Gordon E S  
 SO ADVANCES IN METABOLIC DISORDERS, (1970) 4 229-96. Ref: 195  
 Journal code: 2NR. ISSN: 0065-2903.
- CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Priority Journals  
 EM 197012
- L5 ANSWER 110 OF 114 MEDLINE  
 AN 70162073 MEDLINE  
 DN 70162073  
 TI Metabolic adaptations in meal-fed rats: effects of increased meal frequency or ad libitum feeding in rats previously adapted to a single daily meal.  
 AU Muiruri K L; Leveille G A  
 SO JOURNAL OF NUTRITION, (1970 Apr) 100 (4) 450-60.  
 Journal code: JEV. ISSN: 0022-3166.
- CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 197007
- L5 ANSWER 111 OF 114 MEDLINE  
 AN 70133081 MEDLINE  
 DN 70133081  
 TI Oral anticonception. Side effects and risks.  
 AU Ostergaard E  
 SO ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, (1969) 48 Suppl 1:57-72.  
 Journal code: 1E8. ISSN: 0001-6349.
- CY Sweden  
 DT Journal; Article; (JOURNAL ARTICLE)

LA English  
FS Priority Journals  
EM 197006

L5 ANSWER 112 OF 114 MEDLINE  
AN 70087770 MEDLINE  
DN 70087770  
TI Hunger and satiety.  
AU Morgane P J; Jacobs H L  
SO WORLD REVIEW OF NUTRITION AND DIETETICS, (1969) 10  
100-213. Ref: 249  
Journal code: XQN. ISSN: 0084-2230.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LA English  
EM 197004

L5 ANSWER 113 OF 114 MEDLINE  
AN 70003949 MEDLINE  
DN 70003949  
TI Effects of weight changes produced by exercise, food restriction, or overeating on body composition.  
AU Oscai L B; Holloszy J O  
SO JOURNAL OF CLINICAL INVESTIGATION, (1969 Nov) 48 (11)  
2124-8.  
Journal code: HS7. ISSN: 0021-9738.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 197001

L5 ANSWER 114 OF 114 MEDLINE  
AN 67164838 MEDLINE  
DN 67164838  
TI Defective thirst mechanism secondary to a hypothalamic lesion: studies in a child with adipisia, polyphagia, \*\*\*obesity\*\*\*, and persistent hyperosmolarity.  
AU Travis L B; Dodge W F; Waggener J D; Kashemsant C  
SO JOURNAL OF PEDIATRICS, (1967 Jun) 70 (6) 915-26.  
Journal code: JLZ. ISSN: 0022-3476.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 196709

=> d his

(FILE 'HOME' ENTERED AT 10:08:19 ON 14 SEP 2000)

FILE 'MEDLINE' ENTERED AT 10:08:46 ON 14 SEP 2000

L1 1552 S CAFFEINE  
L2 54 S L1 AND WEIGHT LOSS  
L3 2 S L2 AND REVIEW  
L4 597 S WATER AND WEIGHT AND OBESITY  
L5 114 S WATER AND OBESITY AND EAT?

=> s l5 and review

237562 REVIEW  
L6 4 L5 AND REVIEW

=> d 1-4

L6 ANSWER 1 OF 4 MEDLINE  
AN 2000025951 MEDLINE

DN 20025951  
TI Intense sweeteners and energy density of foods: implications for weight control.  
AU Drewnowski A  
CS Departments of Epidemiology and Medicine, and Nutritional Sciences Program, University of Washington, Seattle, WA 98195-3410, USA.  
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION, (1999 Oct) 53  
(10) 757-63. Ref:  
62  
Journal code: EJC. ISSN: 0954-3007.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals  
EM 200002  
EW 20000204

L6 ANSWER 2 OF 4 MEDLINE  
AN 97300473 MEDLINE  
DN 97300473  
TI Meal frequency and energy balance.  
AU Bellisle F; McDevitt R; Prentice A M  
CS INSERM U341, Hotel Dieu de Paris, France.  
SO BRITISH JOURNAL OF NUTRITION, (1997 Apr) 77 Suppl 1 S57-70.  
Ref: 48  
Journal code: AZ4. ISSN: 0007-1145.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals  
EM 199708  
EW 19970801

L6 ANSWER 3 OF 4 MEDLINE  
AN 85123535 MEDLINE  
DN 85123535  
TI A 13-year \*\*\*review\*\*\* of jejunointestinal bypass.  
AU McFarland R J; Gazet J C; Pilkington T R  
SO BRITISH JOURNAL OF SURGERY, (1985 Feb) 72 (2) 81-7.  
Journal code: B34. ISSN: 0007-1323.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals  
EM 198506

L6 ANSWER 4 OF 4 MEDLINE  
AN 83120251 MEDLINE  
DN 83120251  
TI Bulimia: the binge \*\*\*eating\*\*\* syndrome.  
AU Humphries L L; Wrobel S  
SO SOUTHERN MEDICAL JOURNAL, (1983 Feb) 76 (2) 181-4. Ref: 18  
Journal code: UVH. ISSN: 0038-4348.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 198305

=> s obesity and review and eat?

51496 OBESITY  
237562 REVIEW  
41129 EAT?

L7 108 OBESITY AND REVIEW AND EAT?

=> s l7 and therap?

1971017 THERAP?

L8 50 L7 AND THERAP?

=> d 30-50

L8 ANSWER 30 OF 50 MEDLINE

AN 94225965 MEDLINE

DN 94225965

TI [Psychopharmacologic treatment of bulimia nervosa].

Tratamiento psicofarmacológico de la bulimia nerviosa.

AU Chinchilla Moreno A; Padin Calo J J; Llinares Zaragoza C; Vega Pinero M;

Arias Horcajadas F

CS Servicio de Psiquiatría, Hospital Ramón y Cajal, Madrid.

SO ACTAS LUSO-ESPAÑOLAS DE NEUROLOGÍA, PSIQUIATRÍA Y CIENCIAS AFINES, (1993 Nov-Dec) 21 (6) 211-20. Ref: 85

Journal code: 2AM. ISSN: 0300-5062.

CY Spain

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)  
(REVIEW, TUTORIAL)

LA Spanish

EM 199408

L8 ANSWER 31 OF 50 MEDLINE

AN 93348352 MEDLINE

DN 93348352

TI The effects of dieting on \*\*\*eating\*\*\* behavior: a three-factor model.

AU Lowe M R

CS Division of Clinical Psychology, Hahnemann University, Philadelphia, Pennsylvania 19102-1192..

NC 1 R15 DK 38864-01 (NIDDK)

SO PSYCHOLOGICAL BULLETIN, (1993 Jul) 114 (1) 100-21. Ref: 150

Journal code: QE8. ISSN: 0033-2909.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)  
(REVIEW, TUTORIAL)

LA English

EM 199311

L8 ANSWER 32 OF 50 MEDLINE

AN 93139273 MEDLINE

DN 93139273

TI Opiate antagonists and \*\*\*eating\*\*\* behavior in humans: a \*\*\*review\*\*\*.

AU de Zwaan M; Mitchell J E

CS Department of Psychiatry, University of Vienna, Austria.

SO JOURNAL OF CLINICAL PHARMACOLOGY, (1992 Dec) 32 (12) 1060-72. Ref: 60

Journal code: HT9. ISSN: 0091-2700.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)  
(REVIEW, TUTORIAL)

LA English

FS Priority Journals

EM 199304

L8 ANSWER 33 OF 50 MEDLINE

AN 92347204 MEDLINE

DN 92347204

TI Dexfenfluramine. A \*\*\*review\*\*\* of its pharmacological properties and \*\*\*therapeutic\*\*\* potential in \*\*\*obesity\*\*\* [published erratum appears in Drugs 1992 Jul;44(1):8].

AU McTavish D; Heel R C

CS Adis International Limited, Auckland, New Zealand..

SO DRUGS, (1992 May) 43 (5) 713-33. Ref: 81

Journal code: EC2. ISSN: 0012-6667.

CY New Zealand

DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)

(REVIEW, TUTORIAL)

LA English

FS Priority Journals

EM 199211

L8 ANSWER 34 OF 50 MEDLINE

AN 92312530 MEDLINE

DN 92312530

TI Combination of very-low-calorie diet and behavior modification in the treatment of \*\*\*obesity\*\*\*.

AU Atkinson R L; Fuchs A; Pastors J G; Saunders J T

CS Department of Internal Medicine, Eastern Virginia Medical School, Veterans

Affairs Medical Center, Hampton 23667.

SO AMERICAN JOURNAL OF CLINICAL NUTRITION, (1992 Jul) 56 (1 Suppl) 199S-202S.

Journal code: 3EY. ISSN: 0002-9165.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Abridged Index Medicus Journals; Priority Journals

EM 199210

L8 ANSWER 35 OF 50 MEDLINE

AN 92255839 MEDLINE

DN 92255839

TI The problem of \*\*\*obesity\*\*\* : fundamental concepts of energy metabolism gone awry.

AU Dausch J G

CS National Center for Health Statistics, Centers for Disease Control, Hyattsville, Maryland 20782..

SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, (1992) 31 (4) 271-98.

Ref: 70

Journal code: AF0. ISSN: 1040-8398.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)  
(REVIEW, TUTORIAL)

LA English

FS Priority Journals

EM 199208

L8 ANSWER 36 OF 50 MEDLINE

AN 91264661 MEDLINE

DN 91264661

TI The obese patient.

AU Kaczmarek W

CS WA Faculty of the Family Medicine Programme..

SO AUSTRALIAN FAMILY PHYSICIAN, (1991 Apr) 20 (4) 417, 421.

Journal code: 9EC. ISSN: 0300-8495.

CY Australia

DT Journal; Article; (JOURNAL ARTICLE)

LA English

EM 199109

L8 ANSWER 37 OF 50 MEDLINE

AN 91123619 MEDLINE

DN 91123619

TI Nutrition management for individuals with noninsulin-dependent diabetes mellitus in the 1990s: a \*\*\*review\*\*\* by the Diabetes Care and Education dietetic practice group.

AU Beebe C A; Pastors J G; Powers M A; Wylie-Rosett J

CS St. James Hospital and Health Centers, Chicago Heights, IL 60420..

- SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, (1991 Feb) 91 (2) 196-202, 205-7. Ref: 31  
 Journal code: H6F. ISSN: 0002-8223.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 199105
- L8 ANSWER 38 OF 50 MEDLINE  
 AN 87269200 MEDLINE  
 DN 87269200  
 TI The effect of gut peptides on hunger, satiety, and food intake in humans.  
 AU Smith G P; Gibbs J  
 NC MH-00149 (NIMH)  
 MH-40010 (NIMH)  
 MH-15455 (NIMH)  
 +
- SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1987) 499 132-6. Ref: 20  
 Journal code: 5NM. ISSN: 0077-8923.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Priority Journals; Cancer Journals  
 EM 198710
- L8 ANSWER 39 OF 50 MEDLINE  
 AN 86206581 MEDLINE  
 DN 86206581  
 TI Effects of cholecystokinin and caerulein on human \*\*\*eating\*\*\* behavior and pain sensation: a \*\*\*review\*\*\*.  
 AU Stacher G  
 SO PSYCHONEUROENDOCRINOLOGY, (1986) 11 (1) 39-48. Ref: 52  
 Journal code: QGC. ISSN: 0306-4530.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Priority Journals  
 EM 198608
- L8 ANSWER 40 OF 50 MEDLINE  
 AN 86086410 MEDLINE  
 DN 86086410  
 TI Behavior \*\*\*therapy\*\*\* techniques applied to \*\*\*eating\*\*\*, exercise, and diet modification in childhood \*\*\*obesity\*\*\*.  
 AU Varni J W; Banis H T  
 SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS, (1985 Dec) 6 (6) 367-72.  
 Journal code: HTF. ISSN: 0196-206X.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 198604
- L8 ANSWER 41 OF 50 MEDLINE  
 AN 85206548 MEDLINE  
 DN 85206548  
 TI The \*\*\*therapeutic\*\*\* potential of cholecystokinin.  
 AU Smith G P  
 NC MH-00149 (NIMH)  
 MH-15455 (NIMH)  
 SO INTERNATIONAL JOURNAL OF OBESITY, (1984) 8 Suppl 1 35-8. Ref: 19
- Journal code: GR9. ISSN: 0307-0565.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Priority Journals  
 EM 198509
- L8 ANSWER 42 OF 50 MEDLINE  
 AN 85183614 MEDLINE  
 DN 85183614  
 TI \*\*\*Obesity\*\*\* a family matter: creating new behavior.  
 AU Frankle R T  
 SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, (1985 May) 85 (5) 597-602.  
 Ref: 63  
 Journal code: H6F. ISSN: 0002-8223.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 198508
- L8 ANSWER 43 OF 50 MEDLINE  
 AN 85123535 MEDLINE  
 DN 85123535  
 TI A 13-year \*\*\*review\*\*\* of jejunoleal bypass.  
 AU McFarland R J; Gazet J C; Pilkington T R  
 SO BRITISH JOURNAL OF SURGERY, (1985 Feb) 72 (2) 81-7.  
 Journal code: B34. ISSN: 0007-1323.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals  
 EM 198506
- L8 ANSWER 44 OF 50 MEDLINE  
 AN 84120614 MEDLINE  
 DN 84120614  
 TI The current status of treatment for \*\*\*obesity\*\*\* in adults.  
 AU Stunkard A J  
 NC MH31050 (NIMH)  
 SO RESEARCH PUBLICATIONS - ASSOCIATION FOR RESEARCH IN NERVOUS AND MENTAL DISEASE, (1984) 62 157-73.  
 Journal code: R6P. ISSN: 0091-7443.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 198405
- L8 ANSWER 45 OF 50 MEDLINE  
 AN 83120251 MEDLINE  
 DN 83120251  
 TI Bulimia: the binge \*\*\*eating\*\*\* syndrome.  
 AU Humphries L L; Wrobel S  
 SO SOUTHERN MEDICAL JOURNAL, (1983 Feb) 76 (2) 181-4. Ref: 18  
 Journal code: UVH. ISSN: 0038-4348.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 198305
- L8 ANSWER 46 OF 50 MEDLINE  
 AN 82100958 MEDLINE  
 DN 82100958  
 TI Limitations of behavioral treatment of \*\*\*obesity\*\*\* : \*\*\*review\*\*\*.

and analysis.

AU Foreyt J P; Goodrick G K; Gotto A M  
SO JOURNAL OF BEHAVIORAL MEDICINE, (1981 Jun) 4 (2) 159-74.  
Journal code: J58. ISSN: 0160-7715.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 198205

L8 ANSWER 47 OF 50 MEDLINE  
AN 81007593 MEDLINE  
DN 81007593  
TI Feeding children with Down's syndrome.  
AU Pipes P L; Holm V A  
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, (1980 Sep) 77 (3) 277-82.  
Journal code: H6F. ISSN: 0002-8223.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 198101

L8 ANSWER 48 OF 50 MEDLINE  
AN 79047387 MEDLINE  
DN 79047387  
TI Surgical treatment of \*\*\*obesity\*\*\* : a \*\*\*review\*\*\* of our experience and an analysis of published reports.  
AU Bray G A; Greenway F L; Barry R E; Benfield J R; Fiser R L; Dahms W T;  
Atkinson R L; Schwartz A A  
SO INTERNATIONAL JOURNAL OF OBESITY, (1977) 1 (4) 331-67. Ref: 182  
Journal code: GR9. ISSN: 0307-0565.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LA English  
FS Priority Journals  
EM 197903

L8 ANSWER 49 OF 50 MEDLINE  
AN 79047384 MEDLINE  
DN 79047384  
TI \*\*\*Eating\*\*\* in public places: a \*\*\*review\*\*\* of reports of the direct observation of \*\*\*eating\*\*\* behavior.  
AU Stunkard A; Kaplan D  
SO INTERNATIONAL JOURNAL OF OBESITY, (1977) 1 (1) 89-101.  
Journal code: GR9. ISSN: 0307-0565.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 197903

L8 ANSWER 50 OF 50 MEDLINE  
AN 74097632 MEDLINE  
DN 74097632  
TI A \*\*\*review\*\*\* of behavioral approaches to weight control.  
AU Abramson E E  
SO BEHAVIOUR RESEARCH AND THERAPY, (1973 Nov) 11 (4) 547-56.  
Ref: 57  
Journal code: 9KP. ISSN: 0005-7967.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
LA English  
EM 197405

=> d 20-29

L8 ANSWER 20 OF 50 MEDLINE  
AN 1998046735 MEDLINE  
DN 98046735  
TI Psychological effects of weight cycling in obese persons: a \*\*\*review\*\*\* and research agenda.  
AU Foster G D; Sarwer D B; Wadden T A  
CS University of Pennsylvania School of Medicine, Philadelphia 19104-2648, USA.  
NC RO1 DK50058-02 (NIDDK)  
K02 MH00702-07 (NIMH)  
P30-MH45178-07 (NIMH)  
SO OBESITY RESEARCH, (1997 Sep) 5 (5) 474-88. Ref: 99  
Journal code: CDE. ISSN: 1071-7323.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals  
EM 199802  
EW 19980204

L8 ANSWER 21 OF 50 MEDLINE  
AN 1998036789 MEDLINE  
DN 98036789  
TI Binge \*\*\*eating\*\*\* disorder: clinical features and treatment of a new diagnosis.  
AU de Zwaan M; Mitchell J E; Raymond N C; Spitzer R L  
CS Department of Psychiatry, University of Vienna, Austria.  
SO HARVARD REVIEW OF PSYCHIATRY, (1994 Mar-Apr) 1 (6) 310-25.  
Ref: 77  
Journal code: COW. ISSN: 1067-3229.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals  
EM 199802  
EW 19980204

L8 ANSWER 22 OF 50 MEDLINE  
AN 97276285 MEDLINE  
DN 97276285  
TI Sibutramine: a \*\*\*review\*\*\* of the pharmacology of a novel anti- \*\*\*obesity\*\*\* agent.  
AU Stock M J  
CS Department of Physiology, St. George's Hospital Medical School, University of London, UK.  
SO INTERNATIONAL JOURNAL OF OBESITY AND RELATED METABOLIC DISORDERS, (1997 Mar) 21 Suppl 1 S25-9. Ref: 29  
Journal code: BTX. ISSN: 0307-0565.  
CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LA English  
FS Priority Journals  
EM 199708  
EW 19970803

L8 ANSWER 23 OF 50 MEDLINE  
AN 97149824 MEDLINE  
DN 97149824  
TI Adaptation of African-American cultural and food preferences in end-stage renal disease diets.

AU Patel C; Nicol A  
 CS Total Renal Care, San Leandro, CA, USA.  
 SO ADVANCES IN RENAL REPLACEMENT THERAPY, (1997 Jan) 4 (1)  
 30-9. Ref: 14  
     Journal code: CE2. ISSN: 1073-4449.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
     General Review; (REVIEW)  
     (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 199706  
  
 L8 ANSWER 24 OF 50 MEDLINE  
 AN 96248134 MEDLINE  
 DN 96248134  
 TI Psychological consequences of food restriction.  
 AU Polivy J  
 CS University of Toronto, Mississauga, Ontario, Canada.  
 SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, (1996 Jun) 96 (6) 589-92;  
     quiz 593-4. Ref: 48  
     Journal code: H6F. ISSN: 0002-8223.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
     General Review; (REVIEW)  
     (REVIEW, TUTORIAL)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 199610  
  
 L8 ANSWER 25 OF 50 MEDLINE  
 AN 96122145 MEDLINE  
 DN 96122145  
 TI Exercise and the neurobiological control of food intake and energy expenditure.  
 AU Richard D  
 CS Department of Physiology, Faculty of Medicine, Laval University, Sainte-Foy, Quebec, Canada.  
 SO INTERNATIONAL JOURNAL OF OBESITY AND RELATED METABOLIC DISORDERS, (1995 Oct) 19 Suppl 4 S73-9. Ref: 78  
     Journal code: BTX.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
     General Review; (REVIEW)  
     (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 199605  
  
 L8 ANSWER 26 OF 50 MEDLINE  
 AN 95297398 MEDLINE  
 DN 95297398  
 TI \*\*\*Obesity\*\*\* : a move from traditional to more patient-oriented management [see comments].  
 CM Comment in: J Am Board Fam Pract 1995 Sep-Oct;8(5):426; discussion 427-8  
     Comment in: J Am Board Fam Pract 1995 Sep-Oct;8(5):426-7; discussion 427-8  
 AU Robinson B E; Gjerdigen D K; Houge D R  
 CS Department of Family Practice & Community Health, University of Minnesota  
     Medical School, Minneapolis 55454, USA.  
 SO JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE, (1995 Mar-Apr) 8 (2)  
     99-108. Ref: 75  
     Journal code: 127. ISSN: 0893-8652.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
     General Review; (REVIEW)

(REVIEW, TUTORIAL)

LA English  
 FS Priority Journals  
 EM 199509  
  
 L8 ANSWER 27 OF 50 MEDLINE  
 AN 94351134 MEDLINE  
 DN 94351134  
 TI Diabetes mellitus--a priority health care issue for women.  
 AU Tinker L F  
 CS Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98104..  
 SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, (1994 Sep) 94 (9) 976-85.  
     Ref: 102  
     Journal code: H6F. ISSN: 0002-8223.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
     General Review; (REVIEW)  
     (REVIEW, ACADEMIC)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 199412  
  
 L8 ANSWER 28 OF 50 MEDLINE  
 AN 94333271 MEDLINE  
 DN 94333271  
 TI Consequences of dieting to lose weight: effects on physical and mental health.  
 AU French S A; Jeffery R W  
 CS Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis 55454-1015.  
 NC HL34740 (NHLBI)  
 SO HEALTH PSYCHOLOGY, (1994 May) 13 (3) 195-212. Ref: 190  
     Journal code: EJL. ISSN: 0278-6133.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
     General Review; (REVIEW)  
     (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 199411  
  
 L8 ANSWER 29 OF 50 MEDLINE  
 AN 94305513 MEDLINE  
 DN 94305513  
 TI \*\*\*Review\*\*\* of nocturnal sleep-related \*\*\*eating\*\*\* disorders.  
 AU Schenck C H; Mahowald M W  
 CS University of Minnesota Medical School, Minneapolis.  
 SO INTERNATIONAL JOURNAL OF EATING DISORDERS, (1994 May) 15 (4) 343-56. Ref:  
     42  
     Journal code: BRF. ISSN: 0276-3478.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
     General Review; (REVIEW)  
     (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 199410

=> log y

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		10.88	11.03

STN INTERNATIONAL LOGOFF AT 10:15:58 ON 14 SEP 2000